Skip to main content

Talk Bio

Actionable Insights Powered by AI

Search This Blog

About

Posts

Ipsen signals more deals to continue buying spree

on July 06, 2026

acquisitions buying spree expansion Infrequent Ipsen Kartos Therapeutics M&A Memo Therapeutics Neoplasms pipeline

+

French drugmaker Ipsen has signaled that it plans to continue its current acquisition strategy, with more deals in the pipeline to strengthen its specialty‑medicine portfolio. Sources: Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree Newsroom Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline French biotech company Ipsen to buy Kartos Therapeutics for $450 million Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics Ipsen lines up another bolt-on acquisition Ipsen agrees to buy French biotech company ImCheck Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion [PDF] FY 2025 - Results Announcement - Ipsen Ipsen's $450M blood cancer drug; FDA selects first cohort for “pre ... Ipsen pens €700M deal to buy Swiss biotech for rare disease drug Ipsen completes acquisition of ImCheck Therapeutics, expanding ... Ipsen to Buy Kartos The...

Get link
Facebook
X
Pinterest
Email
Other Apps

Sandoz Tests Direct‑to‑Consumer Sales With Omnitrope Growth Hormone Biosimilar

on July 06, 2026

Biosimilars Ditiocarb DTC generics Growth Hormone liraglutide Omnitrope Sandoz Study models

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Median Technologies' AI tool wins EU nod for earlier lung cancer detection

on July 06, 2026

AI lung cancer CADx CE (Rh group) Cholestasis-edema syndrome, Norwegian type Detection Diagnosis EU eyonis juniper tar Malignant neoplasm of lung Massive Median Technologies screening program

+

Get link
Facebook
X
Pinterest
Email
Other Apps

AstraZeneca seals near $1.8B renal disease pact with CSPC

on July 05, 2026

Al-powered AstraZeneca China Drug Discovery GZMH gene Kidney Diseases milestone payments Pharmaceutical Group RNA, Small Interfering upfront payment

+

Get link
Facebook
X
Pinterest
Email
Other Apps

PureTech Spins Off Celea with $180M Funding to Advance IPF Drug Deupirfenidone into Phase 3

on July 05, 2026

Bayer Capital Management Celea Therapeutics financing characteristics Idiopathic Pulmonary Fibrosis LYT 100 Phase 3 SURPASS-IPF trial pirfenidone pulmonary disease spinoff PureTech Health Rheumatoid Arthritis

+

Get link
Facebook
X
Pinterest
Email
Other Apps

The Francis Crick Institute and Medicines Discovery Catapult Open KQ Labs Applications, Accelerating the Next Wave of Data-Driven Health Innovation

on July 05, 2026

accelerator AI-driven Application procedure August 12 Cohort data-driven health deadline digital health Drug Discovery Francis Crick Institute KQ Labs Medicines Discovery Catapult ninth Precision Medicine

+

Get link
Facebook
X
Pinterest
Email
Other Apps

New Nature Biotechnology Article Highlights the Need for Cell-Cell Interaction Data in AI Biology

on July 05, 2026

Biotechnology Biotechnology perspective article cell-cell project Nature Nature Biotechnology AI biology Nature Biotechnology billion Nature Biotechnology cell-cell interaction Nature Biotechnology Nanovials

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Friday Five: Caris Life Sciences hits MCED market

on July 05, 2026

AI drug discovery Anthropic Axelios sequencer Biological Assay Caris Detect CARIS Life Sciences Claude Science Everlywell Illumina MCED next-generation sequencing Precision Medicine Roche (company)

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Recent US moves add hurdles to US investments in China biotech

on July 05, 2026

BINSA Biosecure Act China COINS Act FIGHT China Act Investments regulatory hurdles U.S.

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Production problems hamper Lantheus bid for FDA approval of LNTH-2501 radiopharma diagnostic kit

on July 05, 2026

CDMO Complete Response Letter diagnostic kit Edotreotide gallium IL31RA gene Lantheus LNTH-2501 manufacturing issues Radiopharmaceuticals third-party facility United States Food and Drug Administration

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

on July 05, 2026

Approved eli lilly Foundayo generic tirzepatide GLP-1 pill IQVIA Oral cavity Prescription procedure slow awareness tirzepatide United States Food and Drug Administration weight loss obesity Zepbound

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Zymeworks agrees to acquire Theravance Biopharma for $929 million in cash plus contingent consideration

on July 05, 2026

acquisition ampreloxetine COPD CVR FGFR1 gene Irish (ethnic group) Theravance Biopharma Yupelri Zymeworks

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Viridian's Lumvoa Gains FDA Nod for Thyroid Eye Disease, Setting Up Clash With Amgen's Tepezza

on July 05, 2026

Amgen Tepezza active chronic thyroid eye disease Lumvoa FDA NALF2 gene subcutaneous elegrobart Thrive THRIVE-2 trials Viridian

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Archive

July 202614
June 2026189
May 2026217
April 2026257
March 2026233
February 2026175
January 2026261
December 2025151
November 2025147
October 2025222

September 2025190
August 2025161
July 2025130
June 2025159
May 2025174
April 2025191
March 2025205
February 2025198
January 202539

Show more Show less

Tags

United States Food and Drug Administration Clinical Trials Approved Obesity gene therapy Neoplasms Vaccines Glucagon-Like Peptide 1 Investments AstraZeneca

Phase 3 Pfizer acquisition Artificial Intelligence Eli Lilly China Pharma Market Merck Roche (company) layoffs sanofi Drug Industry Infrequent Drug Discovery Novartis Biological Factors Leadership manufacturing Drug Development CEO SmithKline Beecham eli lilly Autoimmune Diseases restructuring Cell Therapy IPO Nordisk Appointments Transplant Registry Unified Management Program Acquisition Wegovy drug price expansion Biotechnology Inhibitor COVID19 (disease) Eli Funding Weight Loss Policy Safety CHARGE Syndrome Overall Survival AbbVie Novo Nordisk United States U.S. therapeutic autologous dendritic cells Centers for Disease Control and Prevention (U.S.) Immunology Malignant neoplasm of breast Muscular Dystrophy, Duchenne R&D methionine Antibody-Drug Conjugates semaglutide Precision Medicine Biogen Partnership Zepbound Industry Non-Small Cell Lung Carcinoma Sales - occupational activity Keytruda Alzheimer 's disease Biopharma Dosage Forms Oral cavity Progression-Free Survival Regeneron Immunotherapy Solid Neoplasm Amgen Collaboration Drug Approval Health care facility financial results milestone payments Administration occupational activities CAR-T Prices Board of Directors M&A Accelerated Changing Malignant neoplasm of lung Phase 3 Clinical Trials biotech Clinical Research Elevidys Multiple Myeloma PDUFA Antibodies, Bispecific Moderna innovation rejection Effectiveness Staff UK Weight-Loss Agents earnings pipeline ACIP Biological Markers Biological Science Disciplines Biosimilars Cancer Therapeutic Procedure RFK Jr. BioNTech Myers Nasdaq Trump administration public health medicine (field) EU Growth Phase 2 Schizophrenia Antibodies Gene Modification Gilead J&J clinical development trends qualifier 2025 Financial cost Phase 2 trial Takeda public entity AI drug discovery AI-driven Bayer Johnson & Johnson Metsera genentech in vivo Clustered Regularly Interspaced Short Palindromic Repeats Ozempic Phase 2 Clinical Trials Pricing Radiopharmaceuticals Rare Diseases US research Advisory Committees Capital Clearance Malignant neoplasm of prostate Medicare Monoclonal Antibodies RFK gene biopharma clinical trial failure dosing production squibb Cardiovascular Diseases Dermatitis, Atopic Diabetes Dupixent Myers Squibb NIH Mouse Phase 3 Trial Revolution Medicines Series A Study on Hold competition platform Advice Astellas Gilead Sciences Kidney Diseases Pancreatic carcinoma Phase 3 trial Phase 3 trials Series concerns optimization venture capital Deferred Inflammatory Bowel Diseases MASH Malignant Neoplasms Ophthalmology specialty Phase III Programs - Publication Format Q3 Transition Mutation licensing agreement pharmaceutical manufacturing royalties Autoimmune Biosciences Cautionary Warning Daiichi Diabetes Mellitus, Non-Insulin-Dependent Failure (biologic function) Legal patent Parkinson 's disease net loss supply chain Agonist Amyotrophic Lateral Sclerosis Blackfoot language Colorectal Carcinoma Evaluation Frequency of Responses HHS Health Hims Medicaid RNA Sankyo Senate Series B daraxonrasib development aspects pembrolizumab regulatory tariffs ASCO Adverse event Alopecia CDMO Discontinuation (procedure) Eisai Epilepsy Health Policy Labels (device) Medical Devices Merck KGaA Metabolic Diseases Neuroscience discipline Preventive monitoring RNA Interference Rheumatoid Arthritis Robert F. Kennedy Small cell carcinoma of lung TNFRSF19 gene Telemedicine government orforglipron pharmaceutical tariffs safety profile Antineoplastic Agents Asthma Bio BioMarin Boehringer Ingelheim CBER CFO Duchenne Insilico Medicine Leqembi Malignant neoplasm of urinary bladder Mounjaro Muscular Dystrophy NDA Study models acquisitions federal leadership change melanoma upfront payment venture 2026 Biotherapeutics Bispecific CD276 gene CDER Cells Child Clinical Data Complete Eczema Endpoints Enhertu European (ethnic group) Flagship Hypertensive disease IGA Glomerulonephritis Immunotherapy for cancer Japan Multiple Sclerosis Mutation News [Publication Type] North Carolina Pharmacotherapy RNA, Small Interfering Recommendation Respiratory syncytial virus Response process SMPX gene Technology Ulcerative Colitis alpha 1-Antitrypsin Deficiency alpha 1-antitrypsin cardiometabolic cash runway cost-cutting diagnostics financing characteristics obesity drug patient deaths regulatory approval submission Benefit Burning Mouth Syndrome CAR-T therapy Combined Confirmation Drops - Drug Form Efficiency Facility (object) Financial savings Foundayo LB-102 Leukemia, Myelocytic, Acute Liver diseases MFN Mediation Myasthenia Gravis Nance-Horan syndrome Pauses Proteinuria RNA, Messenger Risk Robert F. Kennedy Jr. commercialization direct-to-consumer early-stage milestones ovarian neoplasm strategic alternatives tirzepatide Alzheimer 's Amylin BTK inhibitor Board appointment Breakthrough Therapy Cancer Research Chronic disease Clinical Discover Drugs, Orphan Germany Homo sapiens IL31RA gene Idiopathic Pulmonary Fibrosis Johnson and Johnson Machine Learning Makary Malignant neoplasm of stomach Myeloid Leukemia, Chronic Neurodegenerative Disorders Psoriasis Series B funding Severe (severity modifier) Surgical construction Target Vaccine Safety Vanda Pharmaceuticals Weight maintenance regimen White House biobucks cellular targeting drug safety drugmakers healthcare technology immuno-oncology medtech oral SERD subcutaneous uniQure Access Agentic AI Antibiotics Antipsychotic Agents Automation BARDA Budgets COPD Commission Detection Elderly (population group) Exit File (record) Generic Drugs Genomics HIV prevention Hidradenitis Suppurativa Impact food supplement Manufacture Mucopolysaccharidosis II PCSK9 inhibitor PD-L1 Phase Phase 1 (qualifier value) Phase 1b Product containing glucagon-like peptide 1 receptor agonist (product) Progressive Pulmonary Fibrosis Pulmonary arterial hypertension RNA Editing Retirement Revenue Scientific Advisory Board Series B financing Spinal Muscular Atrophy Toxicity aspects biotech startups cash position digital health executive order inhibitors merger patent cliff portfolio private equity radioligand therapy trials Bankruptcy Biomechanical compliance Biotech Layoffs CHMP Chief Medical Officer Combined Modality Therapy Dosage First line treatment HIV Hematologic Neoplasms Identifier Infant Injury of liver Insmed Intellia Ivonescimab J.P. Morgan Healthcare Conference JPM26 LDL-C Lenacapavir Licensing Manufacturing Facilities Metastatic castration-resistant prostate cancer Multiple Acyl Coenzyme A Dehydrogenase Deficiency Myasthenic Syndromes, Congenital NVIDIA Narcolepsy Nation Neurology speciality Otsuka Partner in relationship Pediatric brand name Pharmaceutical Services Placebos Prasad Precision - temporal Priority Review Regenxbio Replimune Response Letter Review [Publication Type] Sectioning technique Servier Shakeup Small Molecule SpringWorks Stock Surge Surgical aspects T-cell engager TrumpRx Veradermics Wegovy pill Withdraw (activity) acute approvals aspects of adverse effects biotech industry cancer drugs cardiometabolic diseases corporate partnerships resignation revenue growth reverse merger royalty targets AMT-130 ATTR-CM Abivax Achondroplasia Adangme language Adult Alkermes Antagonist muscle action Attitude Bavarian Nordic Biotech IPOs Blood - brain barrier anatomy Boehringer BridgeBio CLL CNPV CagriSema Cardiovascular system Chronic Kidney Diseases Chronic Lymphocytic Leukemia Chronic Spontaneous Urticaria Chronic multifocal osteomyelitis Complete Response Letter Conditional Congress (U.S. Legislature) Contraceptives, Oral Contract agreement Cystic Fibrosis Diabetes Mellitus, Insulin-Dependent Diffuse Large B-Cell Lymphoma Disease Outbreaks Drug Delivery Systems ESR1 gene Enliven Therapeutics Europe Exelixis Extension Eylea Gardasil Generalized Glycogen storage disease type II Head Hetlioz Hong Kong Huntington 's disease Illumina Incyte Inflammation Influenza Insulin Ipsen MAHA National Security ORR Opdivo PAH PREP gene Patient Death PhRMA Prader-Willi Syndrome Psilocybin RETINITIS PIGMENTOSA 1 Relapsing course Roivant Sandoz Seizures Supplement Trump tariffs VK2735 Vinay Prasad Wave Life Sciences asset assets bidding war biology (field) biomanufacturing delays erbB-2 Receptor executive appointments generative AI generics giredestrant immunotherapeutics jet lag disorder lawsuit manufacturing issues monthly oncology pipeline pharmaceutical innovation precision oncology retatrutide sNDA shionogi sonelokimab strategic strategic collaboration surge treatment-resistant depression AAVS1 gene Agencies Akeso Aktis Alnylam Amlitelimab Anemia Angioedemas, Hereditary Antisense Oligonucleotides Application procedure Autistic Disorder Big Pharma CNS disorder Cessation of life Chief Chief Financial Officer Chinese Language Crohn 's disease DNA Integration Denali Drug Prescriptions ESMO Eikon Epidermal Growth Factor Receptor Event Evidence Forbion Fund Raising GLP-1 receptor GZMH gene Genmab Geographic Atrophy Glycosylated hemoglobin A HPV vaccine Heather Flick Melanson Hepatitis B IPOs Import In complete remission Indirect Indonesian language Inflammatory disorder Injection of therapeutic agent Jazz LDL Cholesterol Lipoproteins Letter [Publication Type] Leukemia Liquid Biopsy Liver Failure, Acute Lundbeck Lupus Vulgaris Lymphoma Maintenance Marty Makary Measles-Mumps-Rubella Vaccine Migraine Disorders MoonLake Nerve Degeneration Neuroinflammation Nuvalent OpenAI PD-1/VEGF PFS Padcev Paul Hudson Peptides Phase 1b trial Phase 3 clinical trial Phase I Clinical Trials Pioneering Post-Traumatic Stress Disorder Presenile dementia President brand of dental material Projections and Predictions Regenerative Medicine Remote Retinitis Pigmentosa Secretary Sentiment Shanghai Statistical Significance TIGIT gene TYK2 gene Talzenna Tavneos Teva Tolebrutinib Translucent Tubulis Ultragenyx Urinary tract infection Zealand Pharma analysts biotech partnerships camizestrant drug review exophthalmos producing substance factor IX first independent review launch mRNA flu manager manufacturability mental health molecular glue nivolumab onshoring oral semaglutide patent infringement perioperative personalized therapies pilot program reorganization shipment startup summit 3-Methylglutaconic aciduria type 2 340B AACR 2026 ADC ADCs AI platform AI-powered AKTS ALV-100 ALV-200 Acquisition (action) Alumis Alveus Therapeutics AnaptysBio Anemia, Sickle Cell Anthropic Anticoagulants Apellis Argenx Ascletis Asymmetric Septal Hypertrophy Atrial Fibrillation Australia Autoimmune thrombocytopenia Avalyn BCR-ABL1 BNT327 Billion Biologics License Application Blenrep Bourla Brain Neoplasms Buckham CE Mark CEOs CIDRAP COVID CSO CVR Camzyos Canada Cancer Vaccines Cancer of Neck Co. Cobenfy CytomX DOGE Datroway Deafness Decision Deep molecular response Department of Health and Dependovirus Disease-Free Survival Disorder of eye Ditiocarb Durham Effect Elamipretide Event-Free Survival Evotec SE Failed Fast Track GIPR gene Galapagos Generative AI Gomekli Guanosine Monophosphate HER2-negative Halda Therapeutics Hallucinogens Halozyme Hannah Anderson Head of US Healthy Heart Diseases Heart failure Hyperphagia Imfinzi Immunization Immunostimulating conjugate (antigen) Impaired India Inflation Reduction Act Innovent Biologics Inosine Triphosphate Ionis Pharmaceuticals J.MD Jr. K-ras Oncogene Kardigan Labcorp License Application Licensing Deal LillyDirect Litigation Long-term Longevity Lung diseases Macular edema due to diabetes mellitus Malignant neoplasm of endometrium Malignant neoplasm of kidney MariTide-like Maziar Mike Doustdar Menopause Metabolic Misinformation Molecular Response Most-Favored-Nation Muscular Dystrophies, Limb-Girdle Myelocytic NECTIN4 gene NLRP3 inhibitors New Jersey Nitroglycerin/Sodium Citrate/Ethanol Solution Novavax ODAC Opioids PDCD1 gene Parabilis Medicines Performance Platform Prescription procedure Project Protein Degradation, Metabolic Q4 2025 R-Series RGX-121 RIPTAC RMAT RNA therapeutics RVMD Regulation Research Projects Retinal Diseases Rick R. Suarez Rocket Science Score Seqirus Sotyktu Stem Cell Therapy Stock Decline Surveys T-Lymphocyte TMEM79 gene Tagrisso Tecentriq Triple Negative Breast Neoplasms Trodelvy Twice a day Type B meeting Uncertainty Vaccine Integrity Project Vascular Endothelial Growth Factor A Ventyx Biosciences Viking Virginia manufacturing facility WDR20 gene Wilmington Delaware Window (physical object) Winrevair Worker WuXi AppTec Yeztugo Zymeworks aldosterone synthase inhibitor annual asciminib authorization baxdrostat capital markets chain disruption collaboration termination commercial coverage - financial contract dealmaking deals decision letter departure - ActRelationshipType deruxtecan developability disbanded drug discounts drug market enforcement engagers enzalutamide financial focal onset seizures funding grant human interleukin-6 license agreement mRNA Vaccine minoxidil muscle-invasive bladder cancer negotiation obesity pill phase advance protocol pre-funded preclinical data protein degrader public health policy ras Oncogene real-world recommendation change regulatory submission regulatory uncertainty resubmission settlement shareholder single-dose schedule small-cell lung cancer stocks strategic review survival tasimelteon tonlamarsen trastuzumab user fees venetoclax workforce reduction zanzalintinib 130-nm albumin-bound paclitaxel 2023 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide AACR ABVX AI drug development AI model AI models AI-enabled ALS AP01 Adjuvant Therapy Adolescent (age group) Affordability Agios Alcon Alexion Altimmune Androgenetic Alopecia Anktiva Antengene Antibody-Drug Apogee Therapeutics Arvinas Assembly (construction) Audit Committee Autoimmune hemolytic anemia B-Lymphocytes BEACON-IPF Bain Capital Beyfortus Biomedicines Biosecure Act Blindness Blood Coagulation Disorders Board Appointment Bovichtus Brazil Breakthrough Therapy Designation Brinsupri CDC CDE California Cambridge Capital Management Capricor Therapeutics Capsid Carcinoma breast stage IV Carlyle Cash Cervical Atlas Chief Legal Officer Childhood Vaccines Chronic pain Clinical Failure Clinical Nurse Specialists Clinician Compass Pathways Contraceptives CordenPharma Corporate governance Cytokinetics DKK1 gene DMD DNA Depressive disorder Diabetic Retinopathy Dianthus Therapeutics Disease Progression Diversity Drug Regulations EBITDA EHA ELAVL2 gene ER-positive Early Diagnosis Ebvallo Eli Lilly backing Empaveli Employee Enflonsia Engaged to be married Episodic Family Turdidae (organism) FibroGen GLP-1/GIP dual agonist GLP-1s Gene Silencing Glaucoma Gross (qualifier value) Groups Gubra Hearings Hemoglobin A1c measurement Hodgkin Disease Hot flushes Hypertriglyceridemia Hypertrophic Cardiomyopathy IL33 protein, human IRA ImmunityBio Immunogenicity (package insert) Immunovant Increase InduPro * * Infantile Severe Myoclonic Epilepsy Injectables Insurance Ira (eukaryote) JPM Jaypirca Journavx KOL Kailera Kelonia Therapeutics Leerink Partners Legal Legend Biotech Liver Liver carcinoma Lynkuet M&A activity MET-097i MYELODYSPLASTIC SYNDROME MacroGenics Malaria Medical Research activity Meeting Mental deterioration Merck & Co. Mississippi (geographic location) Muscular Dystrophy, Facioscapulohumeral Myocarditis NAMs NYSE Nektar Therapeutics Neoplasm, Residual Neurocrine Neuromuscular Diseases Neuropsychiatry New Drug Application Nurix Odyssey Therapeutics Ogsiveo Oligonucleotides Oral Organoids PARP1 gene PD-1xVEGF Pathology Patient access Pediatric Disorder Pennsylvania Personnel Selection Peter Marks Phase 1 trial Phase 1/2 trial Phase 2 clinical trial Phase 2 trials Phase 2b Phase I Plant seeds Pliant Post-Hoc Live Pounds Praxis Precision Medicines Preclinical Prediction Preventive Health Services Primary Biliary Cholangitis Protac Psychological inhibition Q1 2026 Q2 2025 Q3 2025 Quality RAS RAS-driven cancers Rakovina Real-world Evidence Recursion Regulatory Setback Renal Cell Carcinoma Reparative closure Research Personnel Reversal Rinvoq Robotics SanegeneBio Series D Series D financing Sharing (Social Behavior) Sibeprenlimab Skyrizi Small Interfering Sofinnova Standard of Care Stealth BioTherapeutics Structure Therapeutics Subcutaneous Injections Subgroup A Nepoviruses Suspensions Syfovre TMALIN TNBC TSLP gene Tablet Dosage Form Terns Thyroid associated opthalmopathies Transitory Triglycerides UCB UX111 VDPHL01 VRBPAC VTX3232 VTX958 Vabysmo Vaccination Validation Valneva Vas Narasimhan ViiV Healthcare Vinay Vital capacity Vyvgart Wall Street Journal Workforce Reduction YL201 Zolgensma Zorevunersen Zynlonta agonists alfa alixorexton antitrust atezolizumab biotech collaboration biotech sector bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine board changes bounce business career capabilities chief of chikungunya vaccine chronic clinical endpoints conditions contingent value right court decline digital transformation digital twins discontinued docetaxel domvanalimab enlicitide executive leadership expense federal judge first-line high-risk leukemia mCRPC measles muscle preservation nervous system disorder nrSPMS once-daily pandemic preparedness patent settlement payers pharmaceutical companies pharmaceutical marketing pharmaceutical sales pharmaceutical supply chain primary endpoint proposal - intent protein degraders radiopharma rally rates real-world data real-world evidence regulatory compliance remibrutinib reshoring roxadustat rumors scalability seconds shareholders shutdown skipping spending stock crash takeover talks talazoparib targeted therapies tariff tolerability triple agonist upadacitinib update user fee valuation value-based care women 's health zolucatetide AI biotech AI healthcare AI protein design AI-designed drug AP02 ARD-101 ASC30 ASCO26 ASGCT ATR Inhibitor Aardvark Therapeutics Acceleration Acelyrin Acute lymphocytic leukemia Acute onset pain Advanced Melanoma Advanced phase Advocacy Age related macular degeneration Albert Alector Alternative Americas Amylin Analog Amyloid beta-Peptides Amyloidosis Angelini Pharma Antiviral Agents Apellis acquisition Apolipoprotein E4 Apolipoproteins B Arcellx Arcus Arcus Biosciences Arrowhead Pharmaceuticals Ascendis Pharma Atara Ataxia Attention deficit hyperactivity disorder Aurora Therapeutics Automobiles Avidity Biosciences Awareness B-Cell Lymphomas BRUIN BTK Base Editing BeOne Medicines Beak Beijing Bhattacharya Biktarvy Biliary Tract Cancer Bio-Techne Biohaven Biological Assay Biomedical Research Black Populations BlueRock Therapeutics Blujepa Body mass index procedure Burden CBO CD19 Antigens CD3 Antigens CDK2 protein, human CDK4/6 inhibitor CNP gene COAST COMP360 CRDMO CRLs CRO Carboxyamidotriazole Orotate Cardiff Oncology Cardiology discipline Cardiomyopathies Cardiovascular Agents Carvykti Casgevy Cerebrovascular accident Change, Organizational Charles ChatGPT Chief Commercial Officer Chief Operating Officer Chikungunya Fever Childhood Chugai Clinical Trial Design Clinical Trial Failures Complete Response Letters Complicated Compound Concentra Biosciences Congenital Construction worker Crackdown Creative Biolabs CureVac Cylembio Cystic Fibrosis Transmembrane Conductance Regulator DILI Darzalex Datopotamab deruxtecan Deal Value Death of child Deficiency Depletion Dexcom Diabetes Mellitus Diagnosis Does speak Dominance Drug Shortage Drug withdrawal syndrome DualityBio Dyslipidemias Dystrophin ECCO ENPP1 gene ENTR-601 Earendil Labs Ecosystem Edgewise Therapeutics Emma Walmsley Employer Endometriosis Erasca European Hematology Association ( Expectations Express Scripts Eylea HD FCGRT gene FDA-approved Fabry Disease Familial chylomicronemia syndrome Farxiga Fibromatosis, Aggressive Fierce Florida France Freezing Functional Funds Fyodor G-Protein-Coupled Receptors GE HealthCare GLP-1 pill GLP-1/GIP GLP-1/GIP receptor agonist Gastric Inhibitory Polypeptide General Meeting Genome Genome Editing Glioblastoma Glycogen Storage Disease Type IIb HHS layoffs HLD-0915 HRSA Health Planning HealthBench Hemab Therapeutics Hematologic Tests Henlius Hereditary Diseases Hims & Hers Holdings Holly Springs Hormone Therapy Hypercholesterolemia Hypercholesterolemia, Familial Hyperphosphatemia (disorder) Hypertrophic obstructive cardiomyopathy Hypothalamic obesity Imcivree Imdelltra Immune Medicines Immunologic Adjuvants Immunome Improvement Incretins Indication of (contextual qualifier) Induce (action) Inflation Influenza virus vaccine Ingelheim Inhibrx Interferes with Interleukin-13 Interleukin-17 Intrathecal Route of Drug Administration Irish (ethnic group) Isomorphic Labs Ixchiq Janus kinase Jefferies Jeffrey Jennifer Doudna Kailera Therapeutics Kelun-Biotech Kinaset Therapeutics Kirin Kisunla Kymera Kyowa Lab-in-the-Loop Laboratory Laboratory test finding Lecanemab Legos License Litifilimab Liver Failure Localized Logistics Lp(a ) Luke Miels Lupus Erythematosus Lupus Erythematosus, Systemic Lymphodepletion Therapy Lymphoma, Follicular Lytenava MC4R protein, human MHRA Madrigal Pharmaceuticals MapLight Therapeutics Maria Sainz Marty Maryland (geographic location) Massive Medical service Medicare Part D Menin Inhibitor Menkes disease Menlo Ventures Mental Depression Merus Midline (qualifier value) Midomafetamine Mortality Vital Statistics Motion Sickness Myasthenia Gravis, Generalized Myasthenic Syndromes Myopia NIH Narcolepsy type 1 Nasal Spray Nasdaq KARD Neoplasm Metastasis Nephrology Speciality Neurodevelopmental Disorders Neurosecretory Systems New Nkarta Non-Insulin-Dependent Non-Muscle Invasive Bladder Neoplasms Novavax 's Nucala Nxera Pharma OLN324 Obefazimod Obesity Drug Odyssey Olezarsen Oncolytics Orphan Drug Designation Pain management Parity Personalized Personnel Turnover Pharma Industry Pharmaceutical Group Pharmaceutical merger Pharmacovigilance Phase 1/2 data Phase 3 failure Phase II Pipeline Development Piperine Extract (Standardized) Pirtobrutinib Poly(ADP-ribose) Polymerase Inhibitors PreCheck Precision immunology Pressure- physical agent Primary Myelofibrosis Primary Prevention Privacy Prophylactic treatment Protein Domain Protein-tyrosine kinase inhibitor Proteomics Prothena Psoriasis Area and Severity Index Clinical Classification Psychotic Disorders Public Offering Pulse Biosciences R&D pipeline RAP-219 RAPT RDEP REMS ROS1 gene Rapport Therapeutics Ras Inhibitor Reaction Recordati Recovery - action Recurrent respiratory papillomatosis RegenXBio Regulatory Action Regulatory Affairs Reimbursement RemeGen Repatha Repertoire Respiratory physiology Restrictions Revenue Decline Rexulti Rezpeg Rhythm Pharmaceuticals Richard Pazdur Rocatinlimab Rosnilimab Rybrevant SLC6A8 Inhibitor RGX-202 SPAC STELLAR-303 San Diego Saxenda Scholar Rock Science of Chemistry Screening for cancer Secondary malignant neoplasm of pancreas Secretary Nomination Security - service Senate hearing Series A financing Series C Shingrix South San Francisco Spikevax SpinCo ' Spinocerebellar Spinraza Stabilizer - function Stelara Substance Use Disorders Supernus Pharmaceuticals Supreme Court Systemic Systemic Scleroderma T-Cell Receptor T-cell engagers TERN-701 TNFSF15 gene TREM2 TROP2 TUB-040 Taiwan Takeover Tessera Therapeutic immunosuppression Thermo Fisher Thermo Fisher Scientific Tradipitant TransCon Transection (procedure) Trimonthly Trump Truqap Tryngolza UPenn Unable to walk (finding) Uncontrolled United Kingdom United States National Institutes of Health UnitedHealth Group Unresponsive to Treatment Uplizna UroGen VAERS VERVE-102 VG-3927 VX-264 Vaxart Venclexta Vepdegestrant Verona Viking Therapeutics Viral Vector Vision WVE-007 Wages Welireg Winter Park Workers World Health Organization WuXi Xtandi Zenas BioPharma Ziftomenib Zurzuvae abbott adaptation addiction advanced therapies aficamten altretamine/cisplatin/cyclophosphamide protocol amendment asthma drug augmented azacitidine bemdaneprocel benzamide antipsychotic benzamide class bexotegrast binding affinity biomarker testing biotech acquisition biotech merger biotechs branded drugs brensocatib cabozantinib calcium glucarate cancer care cancer drug development care activity checkpoint inhibitors childhood vaccine schedule claims clinical pipeline clinical remission commercial strategy companion diagnostic constraints data integration data manipulation datasets deadline deal degraders deramiocel deucravacitinib digital pathology direct-to-consumer sales discount domestic manufacturing draft guidance drug acquisition drug efficacy drug manufacturing drug shortages election epigenetic reprogramming equity exon federal funding federated learning fibroblast growth factor 21 gMG genetic medicines gepotidacin global expansion governance headquarters healthtech iTeos ianalumab ifinatamab inhaled therapy interleukin-23 investor itepekimab language models liraglutide mRNA Vaccines mechanism pathway meeting merger agreement mergers mid-stage trial mimetics mitapivat nPulse neladalkib nerandomilast net sales neurological diseases nex-z next-generation oHCM obesity trial obinutuzumab oncology partnership onvansertib operating profit oral therapies oral treatment orexins ounce outcomes oveporexton pacibekitug partnership termination patented drugs patient death patient outcomes payment payments petrelintide pharmaceutical acquisition pharmaceutical partnership pipeline reduction pirfenidone platforms platinum-resistant plunge preclinical programs premium prepulse inhibition activity prescription drug costs private placement psychedelic therapy public trust pumitamig reality refusal regorafenib regulatory guidance regulatory science research collaboration review extension rezpegaldesleukin sacituzumab tirumotecan safety review second-line treatment seed fund setmelanotide skepticism small molecule therapeutics specialty medicines statutory scheme stock drop strategic partnership strategic partnerships strategic restructuring strategic shift succession synergies terminations therapeutic areas therapeutic protein threat travel trial design twice-yearly injection type 2 inflammation upfront vaccine overhaul vaccine schedule valproic acid glucuronide vedotin virtual care vusolimogene oderparepvec zidesamtinib zumilokibart 15% 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene 75% 8 AACR25 AAV Vector ABBV-295 ABI-5366 ACR gene ACTN4 wt Allele AERIFY-1 AERIFY-2 AFFINITY DUCHENNE AH 001 AI Platform AI drug design AI factory AI health AI platforms AI tool ALK Inhibitor ALK gene AMD AMG AML ANCA vasculitis ANGPTL3 ANOPHTHALMIA AND PULMONARY HYPOPLASIA AOC AP306 APG777 ASCVD ATG-201 ATTD ATTRv-PN AVLN Abeona Abnormality of mitochondrial metabolism Acadia Accurate (qualifier) Actinium Actuate Therapeutics Adaptimmune Administration of prophylactic statin Administrative action Adoption AdvanCell Adverse effects Adverum Biotechnologies Advisory Panel Age Aging AgomAb Agreement Alagille Syndrome Alameda Headquarters Aldeyra Alexander Disease Alfasigma Allo-Glue platform Allogene Alzheimer Alzheimer 's psychosis Amazona Ambulatory Care Facilities Amgen 's Amicus Therapeutics Amitiza Amplia Amvuttra AnHorn Medicines Analgesics Analgesics, Non-Narcotic Anti-Inflammatory Agents Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibody Therapy Antimicrobial Resistance Antistreptolysin O Anxiety Disorders Apnimed Appia Bio Apple Watch Apply Arbutus Arenaria <Aves> Arrowhead Arthritis, Psoriatic Arthrosi AsedaSciences Asia, Southeastern Atacicept Atopic Attruby Aurinia AutoInjector Autoantibodies Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes Avadel Pharmaceuticals Availability of Aves AviadoBio Avlayah Axpaxli Ayrmid Azafaros B-cell depletion BCG-Unresponsive BGM0504 BIOSECURE BMN BMS BNC210 Batoclimab Baxfendy Bay Area Be6A Beam Therapeutics Becker Muscular Dystrophy Behavior Big Beautiful Bill Bill Anderson Bill Cassidy Bimzelx Bio-Rad BioAge BioArctic BioCapital BioNTech 's BioNeMo Biochemical Pathway Biopharma Advisory Board Biopharma Sentiment Index Biopharma layoffs Bioscience Biotech Innovation Black Box Warning Blackstone Blackstone Life Sciences Blackwell GPUs Blood Pressure Bluebird Bio Boston Scientific Boundless Bio Breakout Ventures Brepocitinib BrightGene Bronchiectasis Bruton 's tyrosine kinase inhibitor Buyout CAN-2409 CD19xCD3 CD388 CE (Rh group) CELMoD CGM CHF CLL-313 CLL-322 CLN-978 CMPX COMPANION-002 CORALreef CORALreef AddOn COVID-19 Vaccines CPOX gene CRL CRSwNP CSU CT-996 CTSC gene CUTX-101 Cadence OTC Cancer Detection Candel Therapeutics Candidiasis, Chronic Mucocutaneous Capacity Capillary Leak Syndrome Capital Partners Caplyta Cardamyst Cardiovascular Risk Cardiovascular event Cartesian Cartography Biosciences Case (situation) Cash Crunch Catalent Catalent Indiana Cataplexy Cavazzoni Celcuity Celea Therapeutics Cell Engineering CellCentric Celltrion Center for Drug Evaluation Centers for Medicare & Medicaid Services Centessa Pharmaceuticals Central Core Myopathy (disorder) Cerebral Edema Chairperson Challenge Chancery Charles River Laboratories Chickenpox Chief Business Officer Chief Product Officer Chief Technology Officer Chimeric Antigen Receptor T-Cell Therapy China-based Chinese biotech Cholestasis-edema syndrome, Norwegian type Cholestatic pruritus Chorionic Villi Sampling Chris Klomp Christophe Weber Chronic inflammatory disorder Chronic low back pain Chronic neutropenia Chronic sinusitis Cidara Therapeutics City of Boston Cityblock Health Claude Claudin-18 Isoform A2 ClearNote Health Clinical Advisory Board Clinical Benefit Clinical Decision Support Clinical Oncology Clinical Services Clinical action Closed Cogent Biosciences Colorado Columvi Commercial Managed Care - Pharmacy Benefit Manager Commissioner Commissioner 's National Priority Voucher Communicable Diseases Communication Community Company Split Comparative Efficacy Compass Therapeutics Complement Inactivating Agents Compounders Comprehensive Conferences Confirmatory Trial Consultation Consumer Safety Continuous Glucose Monitoring System Continuous glucose monitoring Contract Research Organization Conventional (Clear Cell) Renal Cell Carcinoma Corcept Corcept Therapeutics Cosentyx Cost Savings Country Covid vaccine Crohn 's & Colitis Congress Cullinan Customer Cutaneous DB-OTO DEI DEL-AI DELIVER (veterinary product) DLL3 gene DMPK gene DNA Replication DNA medicines DOJ DOR/ISL DT120 ODT DTC Daily Dapiglutide Darovasertib Darzalex Faspro Data Analysis Data Integrity Data Quality Data Safety Daytime Somnolence De Novo Deep Apple DeepHealth Deerfield Management Definium Therapeutics Degrader Delaware Delaware Court Deloitte report Dental Plaque Dentatorubral-Pallidoluysian Atrophy Depression Depression, Bipolar Depression, Postpartum Deramiocel Dermatitis Dermatologic disorders Dermatology field Dermatomyositis Diagnostic Imaging Disease remission Donald Trump Dopaminergic Neurons Dordaviprone Dr. Droughts Drug Approval Process Drug Costs Drug Design Drug Formulation Process Dry Eye Syndromes Dwarfism Dyne Therapeutics EASI EASI-75 EGFR-mutated EMA EMBARK trial EMMI EPI-321 ESMO Congress EV-304 EZH2 protein, human Economics Edema Electrophysiology (science) Elicio Therapeutics Eligibility Determination Eliquis Elivaldogene autotemcel Elon Elraglusib Emergency Contraception Employment Termination Endo Enhance (action) Entrada Enveda Environment Enzymes Epcoritamab Epigenomics Erythrocytes Escherichia coli Esperion Etavopivat Evaluation procedure Evernorth Evotec Excessive (qualifier value) Exdensur Executive Chairman Eye FIBRONEER-ILD FLAURA2 trial FY2025 Fabhalta Factor XI Fair Language Proficiency False Claims Act Familial mitral valve prolapse FcRn Federal Circuit Feedback - system communication Fertility Agents Fertilization in Vitro Fibrodysplasia Ossificans Progressiva Fibromyalgia Fibrous histiocytoma of tendon sheath Financial Forecast Revision Flatulence Focal Food Safety Force Fortress Forzinity Foster City Fosun Pharma Fragile X Syndrome Fraud Friedreich 's ataxia Fujifilm Futility GABA Modulators GEP-NETs GS-1720 GS-4182 Gaithersburg Gastrointestinal Stromal Tumors Gazyva Gemini of Coiled Bodies Gender Gene Expression Gene Mutation Generic Competition Genetic Medicine Genetic Profile Genrix Bio George Tidmarsh Goldcrest Goldman Sachs Gonorrhea GoodRx Google Cloud Gout Suppressants Govorestat Grail Gram-negative bacteria Guidelines HBr HELP Committee HER2-mutant HER2-positive HER2-positive carcinoma of breast HFpEF HIBISCUS trial HIV sales HLX316 HOPE-3 trial HR+ HRS-5346 HYMPAVZI Haisco Hallopeau-Siemens Disease Harbour BioMed Health Care Market Health Care Reform Health Personnel Health agencies Healthcare AI Hearing Heart Helicon peptide platform Hematology (discipline) Hemophilia A Hengrui Hengrui Pharma Hengrui Pharmaceuticals Hepatitis D Infection Hereditary Hereditary Coproporphyria Herpes zoster disease High High-Throughput Nucleotide Sequencing Hikma Pharmaceuticals Hillhouse Investment Management Home environment Hong Kong NDA Hospitalization Hospitals House mice Hua Medicine Humira Hyderabad Hyperlipidemia Hypersensitivity Hypoimmune Technology Hypoparathyroidism I-DXd IBI343 ICOTYDE IDeate-Lung02 IGFBP7 gene IGNYTE trial II IMNM IMVT-1402 IQVIA ITM-11 IZERVAY Iambic Therapeutics Ibex Medical Analytics Ibrance Ideaya Biosciences Idorsia IgG4-Related Disease Illinois (geographic location) Imaavy Imbruvica Immune Immune System Diseases Immune Tolerance Immune response ImmuneOnco Immuneering Immunization Schedule Immunoglobulin IgG4 Immunology pipeline Immunoregulation Impaired cognition Inavolisib Increased Individual Adjustment Infantile Neuroaxonal Dystrophy Infinimmune Infusion procedures Inobrodib Insitro Inspection (procedure) Intact Intellectual Property Intelligence Interim International Interval Intra-Cellular Therapies Invasive Invasive meningococcal disease Inventiva Investigational New Drugs Investor Reaction Io satellite Ionis Isomorphous Israeli (population group) Itovebi J&J 's JCR JNJ-4496 Jakafi Janssen Japanese language Jay Jay Bhattacharya Jeito Capital Jemperli Johns Jon Congleton Jorna Judge KEYNOTE-B15 KGaA KOL Bulletin KOMET-001 KRP KRP-M223 KRRO-110 KRSA-028 KT-621 KYV-101 Kai Beckmann KalVista Kartos Therapeutics Karyopharm Therapeutics Kennedy Kerendia Kevin Tang Kezar Life Sciences King Kisqali Kissei Korro Bio Korsana Biosciences Kresladi Kyorin Kyowa Kirin Kyverna LAVA LB2501 LBCL LBRX LEAP LGBTQ+ LUMRYZ LYT 100 Languages Lars Fruergaard Jørgensen Late stage Laurie Stelzer Lawyer (occupation) Lazcluze Leadership Transition Lean Mass Leukocyte adhesion deficiency type 1 LifeMD Lifting Lightning Step Lila Sciences Lilly Gateway Labs Lilly TuneLab Lilly collaboration Lilly partnership Limited (extensiveness) Linerixibat Lipid Nanoparticles Liver and Intrahepatic Biliary Tract Carcinoma London Long Intergenic Non-Protein Coding RNA Lonza Lung-01 Lunsumio Lupus Erythematosus, Cutaneous Lupus Nephritis Lyme Disease MADRS score MAGNITUDE trial MASP-3 Inhibitor MBX Biosciences MCED MEK MEMO1 gene MET-233i MIBC MPLT MRGPRX2 gene MRT-6160 MSTAR MYOTONIC DYSTROPHY 1 Mabwell Major Depressive Disorder Malignant neoplasm of anus Mallinckrodt Mantle cell lymphoma MariTide Marketing Authorization Massachusetts (geographic location) Measures Mechanism Framework MedKey Median Technologies Medical Specialities Mehmet MeiraGTx Mendra Meningococcal vaccine Mental Recall Mesenchymal Stem Cells Metabolic Syndrome X Metastasis from malignant neoplasm of colon and/or rectum Metastatic Pancreatic Ductal Adenocarcinoma Mexico Microbicides Microbiome Microglia Microsoft Mike Doustdar Milestone Miller Dieker syndrome Mineralys ModeX Molecular Glue Degrader Monte Rosa Therapeutics Montgomery-Åsberg Depression Rating Scale Monthly (qualifier value) Morning After Pill Mother (person) Mozafancogene Autotemcel Mucopolysaccharidosis Type IIIA Multiple Sulfatase Deficiency Disease Musk secretion from Musk Deer Mycoses Myeloid cell engager Myotonic Dystrophy Myqorzo N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide NALF2 gene NBD1 NEFL gene NEJM NEREUS NPM1 Nasdaq EIKN Nasdaq PBLS Nasopharyngeal carcinoma National Priority Voucher Navsunli NervGen Pharma Neuphoria Neuregulins Neurodegeneration Due To Cerebral Folate Transport Deficiency Neuroendocrine Tumors Neurofibromatosis 1 New Approach Methods New-onset refractory status epilepticus NewAmsterdam Pharma NewCo NewLimit Newleos Nimbus Therapeutics Note (document) Novo Novo Nordisk Foundation OBBBA OPKO Health OTOF gene Obesity care ObesityWeek 2025 Obexelimab Obicetrapib Obstetric Delivery Obstructed Ocular Toxicity Office OliX Ollin Ollin Biosciences Omeros Oncologic Drugs Advisory Committee Opdualag Open OpenFold Consortium OpenFold3 Options Optogenetics OrbiMed Orca Bio Orexin Receptor Agonist Organization administrative structures Organon Orionis Biosciences Ornithine carbamoyltransferase deficiency Orthopedics Oura Oura Ring Ouro Medicines Overweight PANSS PBMs PCSK9 protein, human PD-1/VEGF bispecific antibody PD-L1xVEGF PF-08653944 PHD1/2 inhibitor PIK3CA mutation PLK1 gene PLN-101095 PLRX PM359 PP405 PROBODY PROTEUS trial PTC518 PWS PYRUKYND Pancreatitis, Acute Papzimeos Paragon Therapeutics Parkinson Disease Paroxysmal supraventricular tachycardia Partial Parts per million (qualifier value) Patent extension PathAI Paul Offit Penmenvy Pericardial effusion Personalized cancer care Persons Petosemtamab Phage Therapy Pharma AI Pharmaceutical Research Pharmacy facility Phase 1/2a Phase 2a trial Phase II B Trial Phase IIa Philadelphia Philips Phobia, Social Physical and emotional exhaustion state Physicians Pick Disease of the Brain Pierre Fabre Pipeline Progress Pivot Device Plexiform Pliant Therapeutics Pluvicto Podnosis Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Poolbeg Post-transplant lymphoproliferative disorder Postpartum Precigen Prediabetes syndrome Predictive analytics Pregnant Women Presentation Preventive Care Previous Primary Health Care Primary Hypersomnia Primary amyloidosis Prime Medicine Principles Priovant ProfoundBio Progranulins Project NextGen Promotion (action) Protein Degradation Protein Engineering Protein Tyrosine Kinase Proteins Protocols documentation Prussia Public Preparedness Pulmonary Pulmonary Hypertension Q1 2025 QIAGEN Quality of life Qyuns Therapeutics R1 Therapeutics RAS inhibitors RC148 RECONNECT RGX-111 RNA, Circular RNAi medicines RP-A501 RSV RTW RadNet Radiant heater Rani Therapeutics Rating (action) Records Recruitment Recurrence Recursion Pharmaceuticals Relapse Relocation of home or business Report (document) Republican Republicans Respiration Disorders Response Letters Retevmo Retinal Vein Occlusion Rett Syndrome Reunion Revenue Upgrade Rezdiffra Rezpegaldesleukin Rhapsido Rigel Pharmaceuticals Rilzabrutinib Rising Risk Management River Laboratories Robert Langer Rogaine Romvimza Rybelsus Rytelo SA030 SABCS SENS-601 SERENA-6 trial SG&A SK Biopharmaceuticals SLL SNCG gene SOLSTICE SOPHiA GENETICS SPN-820 SPS STAR-221 STARGLO STAT6 degrader SV Health Investors SVP SYMPHONY-1 trial Salts Samsung Samsung Biologics Sanofi Ventures Saphnelo Sarcoidosis Scemblix Schrödinger Scientific Study Scott Gottlieb Seagen Seaport Therapeutics Sebetralstat Selective Estrogen Receptor Down Regulator Self Confidence Senate Finance Committee Sense of identity (observable entity) Sentynl Therapeutics Septerna Serapha Bio Sernova Services Shockwave Medical Short Bowel Syndrome Sidewinder Therapeutics SigVie-002 Simcere Singapore Sionna Site SkySTAR platform Skyhawk Skysona Sleep Sleep Disorders Sobi Social Welfare Social stigmata Sodium Channel Blockers Soleno South Korea Spinal Cord Injuries Spinout St. Louis Standard (qualifier) Standard BioTools Star Therapeutics Stargardt's disease Steroids Stewardship Stifel Stiff-Person Syndrome Stivarga Stock Crash Stock exchange Stoke Therapeutics Subcutaneous Keytruda Sun Pharma Sunwave Super Bowl ad Sustained-release Mitomycin C Hydrogel Formulation UGN-102 Suzetrigine Svalbard Switzerland Symbravo Synthetic Biology Synthetic Lethality Syringes TALAPRO-2 TAR 200 TCE TERN-601 TNFRSF4 gene TP53 gene TPTE2 gene TRANSCRIPTION FACTOR TSND-201 TSRA-196 TTR wt Allele TUB-030 TYK2 inhibitor Tabelecleucel Taiho Tango Therapeutics Targeted Protein Degradation Targeted Therapy Tazverik Team Tecartus Tecelra Tecvayli Telix Tempus AI Tenaya Therapeutics Tender Tension Terray Therapeutics Testing Texas Thalassemia Theranostics Theravance Biopharma TimeLine Fluoride Releasing Resin Tissue damage Transaction Transcend Therapeutics Translarna Treating Treatment Protocols Treeline Tremfya Trontinemab Trulicity Trump drug pricing Trump loyalists Trump vaccine schedule Tuberculosis TuneLab Type 2 Tyruko U.S.-China UAE UBT251 UGX-202 US tariffs USPSTF Union United States Federal Trade Commission United States Health Resources and Services Administration United Therapeutics Universities Unnatural Products Unresectable Unsolicited Adverse Event Utah VANQUISH-1 VESALIUS-CV VESPER-3 VGA039 VIKTORIA-1 VTCN1 gene Vaccine Development Vaccines, Combined Valo Health Variant Varseta-M Vascular Diseases Ventus Therapeutics Veppanu Vera Therapeutics Verona Pharma Verzenio Viable Vigil Vimkunya Vir Biotechnology Viridian Voxzogo Voyxact Vykat Vykat XR Vyndamax Vyne WEE1 gene WVE-006 Wakefulness Walmart Pharmacy Wayrilz Wellcovorin Woman Workforce - population group Wugen XLRP Xocova YUVIWEL Yale Yescarta YolTech Ypsomed Yupelri ZEVASKYN ZYCUBO Zag Bio Zai Lab Zaltenibart Zepzelca Ziihera Zilganersen Zimmer Biomet Zydus Lifesciences Zynyz access program acute liver injury acute pain treatment ad campaign adulteration agentic AI algorithm all-stock alpha therapies alpha-Synuclein amisulpride ampreloxetine amycretin anti-IgE anti-TL1A anti-TSHR antibody anti-seizure medication anti-tumor activity antiarrhythmic peptide antibody engineering antibody libraries antitrust lawsuit apitegromab appeal at-risk atebimetinib avacincaptad avacopan belrestotug benzamide bexobrutideg bezuclastinib bile duct syndrome biopharma executives biopharmaceutical development biopharmaceutical industry biopharmaceutical manufacturing bioprocessing biotech closures biotech downturn biotech partnership biotech startup bispecific ADCs bispecifics black box blockbuster drugs blood thinner board chair bone health bota-vec boxed bretisilocin brexpiprazole business development buyback campus cancellation cancer discovery cancer pipeline capitalization capsule (pharmacologic) carbetocin cardiometabolic disease cardiometabolic health cardiovascular pipeline cell line development cell renal cell carcinoma cell therapy manufacturing central venous catheter (CVC) sets charge amounts checkpoint inhibitor cholesterol chronic hand eczema cibotercept claseprubart clinical AI clinical program clinical strategy clinical trial design clinical trial termination clinical-stage assets cold chain logistics competitiveness compounding pharmacies continuous glucose monitor contract manufacturing corporate strategy cost management cost-cutting measures danuglipron data privacy day dazucorilant de novo design debt decentralized decision delay decitabine denosumab departures dexamethasone diabetes care diabetes drug diranersen direct-to-patient disease prevention disease treatments disruption divestment dividend domestic drug manufacturing domestic partnerships dorzagliatin dosed dostarlimab drug applications drug development halt drug launches drug rejection drug response drug spending drug-resistant epilepsy dry AMD dual-targeting CAR-T dupilumab durability early development economic impact elecoglipron envudeucitinib etripamil exacerbations executive appointment executive promotions executive transition executives exemptions expert experts eyonis fast-track approval felzartamab fentanyl crisis fill-finish financial performance firings first-in-class first-in-human first-line therapy functional cure gains gastroesophageal adenocarcinoma gedatolisib gemcitabine gene targets generic pharmaceuticals glucagon glucokinase activator goal growth outlook growth strategy guidance cut hair regrowth health data health disparity healthcare investment heart health high-risk groups high-throughput screening human antibody human papillomavirus hydrocortisone iRhythm iberdomide ibogaine icotrokinra impairment charges import alert improvements incretin drugs inebilizumab infigratinib infringement injunction investors islatravir islet isononanoyl oxybenzene sulfonate issues leader leadership appointments leadership shakeup leases leucovorin lexicon listings liver transaminase liver-targeted RNAi lobbying loncastuximab tesirine long-acting lonvo-z lorigerlimab losses low-grade mCRC mRNA cancer mRNA therapies macrocyclic peptides maintenance trial manufacturers manufacturing capacity masetecan mass layoffs medical AI medical technology meloxicam methodologies military companies milvexian mirdametinib mitomycin mo-rez mocertatug molecular glue degraders molecular glues multimodal AI multispecific antibodies namilumab narmafotinib navepegritide net income next-generation biologics next-generation sequencing nivisnebart nomination non-opioid pain drugs older once-monthly operational ophthalmic preparation oral drug oral obesity drugs oral peptides oral small molecule oral therapy p300/CBP inhibitor patent cliffs patient safety pegcetacoplan pegol pegozafermin pemvidutide persevERA personal reasons personalized cancer pharma innovation pharma partnerships pharma revenue pharmaceutical competition pharmaceutical litigation pharmaceutical manufacturers pharmaceutical negotiations pharmaceutical partnerships pharmaceutical regulation pipeline cutbacks pipeline focus pipeline pivot pipeline prioritization pituitary adenylate cyclase activating polypeptide placebo-controlled trials platform technology designation point-of-care portfolio strategy povorcitinib precision cancer preclinical pipeline predictive predictive models prescription discounts price cut prime editing priority review vouchers probationary workers product profit guidance protein design protein design AI protocol design quality management ranibizumab real-time monitoring rebound recipients recombinase reconciliation recurrence prevention reforms registrational development regulatory challenges regulatory decisions regulatory environment regulatory filing regulatory filings regulatory hurdles regulatory policy regulatory review regulatory setback regulatory strategy relacorilant removal technique repeal reproductive healthcare reproxalap requirements research funding reshuffle resilience revenue guidance rezetecan ribupatide risk mitigation risk-benefit analysis rizatriptan ruxolitinib sales growth search - EntityNameUse sertraline setback sevabertinib sigvotatug vedotin site closures skinny label small molecule therapy solbinsiran sparsentan spindle orientation checkpoint stake startups stop work strategic brands strategic realignment subcutaneous delivery subcutaneous formulation subscription program sustainability tafamidis takeover taletrectinib tariff exemption tazemetostat tenosynovial thimerosal third quarter 2025 tividenofusp topline tourmaline tovecimig treatment failure treprostinil palmitil inhalation powder trispecific antibody troriluzole tulisokibart tumor targeting tumor-activated tumor-selective antigens underwriters underwritten upsized uridine triacetate ustekinumab uveal melanoma vaccine access vaccine deaths vaccine panel vaccine politics vaccine sales varsetatug vasomotor symptom vatiquinone velinotamig vepdegestrant vera vomiting prevention vormatrigine vosoritide voucher program warning letters webinar weight-loss weight-loss pill wet AMD wet age-related macular degeneration winners working capital wound care xRNA zasocitinib zimberelimab zimislecel (3beta * * European Life Sciences Coalition * * Global Expansion * * * * Riad Mishlawi * * * * Vivek Ramaswamy * * * * atopic diseases * * * * functional cell 0% 10 mg 100% 15B 1964 1L pancreatic cancer 2-aminoethylmethyl sulfone 20% 200 2024 2026-2035 2032 22C3 24-Hour Data 28.7% 3 serotype 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one 30% 35 36% 4D Molecular Therapeutics ' 5,6-methylenedioxy-2-aminoindane 50–59 52-week results 55% 5B 5alpha)-isomer 6-amino-1-hydroxyhexane-1,1-diphosphonate 7.5 mg 8(a 8.875% 80% 90% 95% A&B/SARS-CoV-2 AA Signature AAAAI AACR-NCI-EORTC AAD AAER AAPS NBC 2026 AARD gene AARP AAV antibodies AAV gene therapy AAV-AIPL4 AAV-based gene therapy AAVB-081 AAVantgarde AAVrh74 AAVrh74 vector AB-1005 AB-2100 AB001 ABI-4334 ABP-102 ABPI ABS-0871 ABS-1230 ABTECT ABTECT-1 ABTECT-2 ABX464 ACCENT trial ACCESS II ACHIEVE-1 ACI-7104.056 ACP-101 ACR-2316 ACR50 ACUA AChR-Ab AD109 ADA25 ADAM11 protein, human ADAMTS-5 ADAPT-PD study ADARx ADEL ADEPT-2 trial ADMET ADPD AFFINITY DUCHENNE trial AFFIRM-1 AFFIRM-1 phase 3 trial AFPs AGCM Biogen investigation Stratify test AGXT gene AHA AI Assist AI Factories AI Proteins AI Stethoscope AI agents AI antibiotic discovery AI automation AI biomarker AI biopharma AI clinical trials AI collaboration AI foundation model AI guardrails AI health app AI healthtech IPOs AI humanoid robots AI imaging AI lab AI lung cancer AI oncology imaging AI refills AI safety AI scientist AI skills AI solutions AI supercomputer AI therapeutics AI tools AI ultrasound AI workflows AI-Based Protein Design AI-Powered Test AI-based AI-based drug discovery AI-designed AI-designed drugs AI-designed molecules AI-designed pill AI-discovered drugs AI-engineered antibody AI-generated AI-guided AI-native platform AI-powered diagnostics AI-powered drug discovery AI-powered healthcare AI-powered solutions AI-ready AI/ML-enabled product AIM-MASH AIR-001 AJ1 AK006 AK0406 AKAP9 protein AKAP9 protein, human AKT inhibitors AKY-1189 AL ALK7 ALKOVE-1 trial ALPHA3 ALPHA3 trial ALT-positive ALTO-101 ALTO-203 ALX ALX2004 ALZ-801 AMGN AMONDYS AMP KRAS Vaccine ELI-002 AMPA receptor modulator AMPA-PAM AMPLIFY-7P trial AMT-191 AMWC AMX0035 AN2 ANDA ANNE ANX005 AP3 APG-5918 APIs APJ APLAS APOE program APOL1-mediated kidney disease APRIL inhibitor AQUILA study AR navigation ARC-EX System ARCT-032 ARD-201 ARG-007 ARIA ARIA risk ARIA-E ARID1A mutation ARO-ALK7 ARO-C3 ARO-INHBE ARO-PNPLA3 ARO-SNCA ARPA-H grant ARROS-1 trial ARTBIO ARTV ASC41 ASCEND trial ASCENT ASCO GI 2026 ASCO preview ASCO-GU ASCO25 ASMB ASPIRO trial ASPR ASTX029 ATG-022 ATG-125 ATG-207 ATI ATLAS-UC ATMP regulation China ATN ATNM-400 ATR ATR/mTOR Inhibitors ATSN-101 ATSN-201 ATTAIN-2 ATX01 AURKA inhibitor AURN001 AVB-114 AVD-104 AVTX AVZO AWS HealthLake AXS-14 AZD0120 AZD0780 AZD5004 AZSTARYS Abata AbbVie CEO AbbVie New Jersey AbbVie Robert Michael Abbas Kazimi Abbisko Cayman Abbisko Therapeutics Abbreviated New Drug Application Abcam Abdominal Fat Abe Bassan Abecma AbelZeta Abeona 's Abetalipoproteinemia Abivax falls Abivax stock Absci Academia (organization) Academy of Pediatrics Accelerate Diagnostics Accelerated Approval Accord BioPharma Accuray Achieve Life Sciences Acne Vulgaris Acoramidis Acrivon Acrobat Genomics Acromegaly Act of Documentation Actimab-A Acting Actinium Pharmaceuticals Actio Actithera Active Activin E :* * Actuate AcuCort Acute leukemia Adagene Adaptive Biotechnologies Adcetris Adcomm Addictive Behavior Adenosine deaminase deficiency Adenovirus Infections Adherence (attribute) Adherence To Medication Regime Aditum Adjunctive Orthodontic Procedure Adjuvant Melanoma Admilparant Adolescence AdvaMed Diabetes Sector Advanced Imaging Suite Advanced Manufacturing Technology Advanced Therapy Medicinal Products Advanced Urothelial Carcinoma Adverse reaction to drug Advertising (activity) Advisory Board Advita Ortho Aerska Afami-cel Afimetoran Africa Afya Limited Agenesis of corpus callosum Agentic Harmonization Assistant Aggressive Aggressive Periodontitis Agilent Agios Pharmaceuticals Agitation Ahmed ElNawawi AiTEM AilsynBio AimedBio Ainnocence Airna Ajax Health Ajax Therapeutics Ajay Nirula Akeega Akeso 's Al-powered Alamar Biosciences Alan Ashworth Alan Sandler Alarm device Albert Bourla Alberto Lopez Toledo Alchemab Alcohol Use Disorder Alcohol abuse Alcohol or Other Drugs use Aldose Reductase Inhibitor Alejandro Weinstein Alexei Algen Biotechnologies AlgoTx Alkeus Allakos Allergan Allergy Specialty Allergy to peanuts Allison Candido Allogeneic Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880 Allogeneic bone graft Alloimmune thrombocytopenia Alluminox Alma AlphaDirect technology AlphaFold AlphaLab AlphaMedix Alphabet Altanine Alteogen Alternative Funding Programs Altman Alto Neurosciences Altuviiio Alumni Alva Therapeutics Alveltamig Alvotech Alyftrek AlzeCure Alzey investment cut Alzheimer 's agitation Alzheimer 's disease psychosis Alzheimer 's treatment AmBisome Amar Thyagarajan Amarin Amarin Pharma Amazon Health Amazon Pharmacy Amazon Web Services AmbioPharm Ambros Therapeutics Ambrosia Ambrosia Biosciences Ambrx American College of Cardiology American Depositary Receipts American Epilepsy Society 2025 AmericasMedicines.com Amethyst Amezosvatein Amgen Tepezza active Amgen Uplizna Amgen settlement Amit Singal Ammonia level finding Amneal Amolyt Amondys Amphastar Amplify trial Amsterdam facility Amtagvi Amylin Candidate Amyloid-targeting therapy Amylyx AnTenGager Anabolism Analog Analysis of substances Anaphylm Anatol Andembry Andreas Goutopoulos Andreas Wallnöfer Andreessen Horowitz Andrew Grethlein Andrew O Andrew Witty Andy Thomas Anesthesia procedures Ang2 Angela Breton Angelini Industries Angiotensinogen Anima Biotech Animal Health Animal Testing Animal Welfare Animal mane Ankylosing spondylitis Ankyra Therapeutics Ann Arbor Anne Anne Wojcicki Annexon Anniko Annual Reports Anomaly Ventures Ansa Ansa Biotechnologies Anselamimab Ant Afu Ant Group Antares Antares Therapeutics Anthos Anthropological Culture Anti-BTN3A Agonistic Monoclonal Antibody ICT01 Anti-CD19 Monoclonal Antibody Anti-CD36 mAb Anti-CD47 Monoclonal Antibody AK117 Anti-CD52 Monoclonal Antibody ALLO-647 Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 Anti-Kickback Statute ( Anti-OX40 Hexavalent Agonist Antibody INBRX-106 Antiandrogen therapy Antibiotic Resistance Antibiotic Resistance, Microbial Antibiotic therapy Antibody Therapeutics Antidepressive Agents Antifungal Agents Antineutrophil Cytoplasmic Antibodies Antitrust Probe Anumana Anxiety Anything Anzupgo Apheris ADMET Network Apis (invertebrate) Apnea Apollo robot Appeals court decision Apple App Store Apple Health Applied Pharma Apptronik Apretude Aquestive Therapeutics Aquipta Aqvesme Araris Arbitrating Arbuckle Arc Bio Arch Biopartners Arch of foot Archimed Architecture Arcturus Arcturus Therapeutics ' Arena BioWorks Areteia Arexvy Arginine Vasopressin-Neurophysin II Preproprotein Argo Biopharma Arikayce ArkBio ArsenalBio Artera Arteriosclerosis Arthritis Artificial (qualifier value) Artificial cardiac pacemaker Artiva Biotherapeutics Asarina Ascenta Capital Ascentage Pharma Ascidian Therapeutics Ashiq Khan Asia-Pacific Asian Americans Asian Indian AskBio Aspect - Kind of quantity Aspen, Bach Flower Essence Assertio Assertio Holdings Astellas Pharma Astex AstraZeneca 's Astria Astrin Biosciences AstroRx ® Atai Life Sciences Atara 's Atara Biotherapeutics Ataxia Telangiectasia Ataxia, Spinocerebellar Athetoid cerebral palsy Athlone facility Atirmociclib Atropos Health Atsena Attack device Attention Attenuated by (contextual qualifier) Atypical Aubrey C. Galloway Audit Committee Chair Augmented Reality August 12 Aurion Biotech Autism Spectrum Quotient Autoimmune Alliance Autoimmune Chronic Hepatitis Autoimmune Therapies Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F Autolysosome Automated (qualifier value) Autonomous Research Auvelity Avacta Avadel Avadel acquisition Avalo Therapeutics Avantect Avantect ® Pancreatic Cancer Test Avastin Avenzo Avenzo Therapeutics Average Avicanna Avidity Avobis Bio Avoro Awards Awiqli Axelios sequencer Axial Axplora Axsome Axsome Therapeutics' Ayvakit Azure A³ Strategy B Cell Llama B cell immunomodulator program B-Well trials B-cell Select ™ technology B7-H3-targeted sialidase B7H3/PTK7 bispecific TOP1 BAFF‑R BAG3-associated BATNA BBB BBB shuttle BBI-355 BBI-825 BBOT BBP-418 BCG Vaccine BCG-unresponsive BCL-2 Inhibitor [EPC] BCL11A gene BCL6 gene BCMAxCD19 BCR BDTX-4933 BEAM-302 BEHOLD-1 BEXMAB BGI BHB-1893 BHV-7000 BI BIC/LEN BII BINSA BIO board BL-B01D1 - 303 BLA BMB-101 BMB-105 BMRN BMS-986177 BMS-986322 BMS-Hengrui BNT211 BPC 157 BPI gene BPL BPSI BRCA BRCA2 gene BRENTUXIMAB BROADWAY BROADWAY trial BT-267 BT-409 BTK degrader BTKi BTN3A BW-20829 BX211 BXLS VI BYD Baby KJ Bacillus cereus Bacterial Endocarditis Bacterial Infections Baebies Baker Balinese language Bambusa Therapeutics Bangalore plant Barakat syndrome Barinthus Barrow Neurological Institute Barzolvolimab Basketball game Basking Ridge Bassas da India Bausch + Lomb Bausch Health Beacon Beat Becker Hewes Beeline Beginning Behcet Syndrome Belén Belén Garijo Bench International Benedikt von Braunmuehl Bepirovirsen Beqalzi Beqvez BerGenBio merger Berkeley Berkeley Vincent BetterHelp Bettis Bharat BiLockCatcher Bial Bias (Epidemiology) Bicara Therapeutics Bicillin L-A Bicycle Bicycle Health Bicycle Therapeutics Big Data Big Pharma investors Bilirubin Bill Adams Billion Collaboration Billioux Binding action Bintrafusp alfa Bio + Health Bio-Informatics Bio-Thera BioAtla BioCity BioClec BioCryst BioGPU BioPorto BioSpace BioStem BioVU BioVie BioXcel Therapeutics Biochemistry Biocodex Biocon Biologics Bioconjugation Platform Biocytogen Biodexa Bioeconomy Bioepis Biogen CEO Biogen Tysabri Sandoz Biohaven troriluzole Bioliberty Biological Availability Biological Response Modifier Therapy BiomX Biomanufacturing Strategy Biomedicine Biomolecular AI Bionyra Pharma Biopharm Biopharma regulatory issues Biopharma trade war Biopharmaceuticals Biosafety Bioshield Biotech Competition Biotech Fundraising Biotech Layoff Tracker Biotech pipeline shift Biotechnology Advantage Biotechnology perspective article Bipartisan Support Bipolar I disorder Bitopertin Bivamelagon Bizengri Blackwell Ultra GPU Bladder Risk Blastic plasmacytoid dendritic cell neoplasm Blepharitis Blood Blood Pressure Insights Blood Transfusion Blood coagulation tests Bloomington Indiana Blue Owl Healthcare Blueprint Medicines Board Directors Board Resignation Board change Boards (medical device) Bobby Hunter Body Composition Boehringer Ingelheim Germany Boltz-1 Boltz-2 Bone Density Bone Diseases Boost Boston Pharmaceuticals Boston event Boundless Brain Brain Delivery Module Brain Injuries Brain Research Brain hemorrhage Brain stimulation Brain-Computer Interfaces Brain-Penetrant Drug BrainSpace BrainTransporter platform BrainTransporter technology Brainomix Brainomix 360 Brainshuttle Braveheart Bio Breakthrough Device Designation Breast Acoustic CT Brendan Doran Brenig Therapeutics Brexit impact Breye Therapeutics ' Brian Armstrong Brian Cherry Brian McKelligon Brian Thomas BridGene BridgeBio Pharmaceuticals Briggs Morrison Bright Minds Biosciences Brilaroxazine Brilliance Studies Bristol-Myers Squibb BroADen Phase 1b trial Broad Institute Bruce D. Forrest Bruin-CLL-314 Bruker Corporation Bruton's Tyrosine Kinase Inhibitors [MoA] Bullous pemphigoid BurstDR Business Update Call Bysanti C-CAR031 C-reactive protein C-suite C-suite changes C1QA gene C3 G C3 complement inhibitor C3 glomerulopathy C4 Therapeutics C5 inhibitor CAB CABA-201 CADENCE study CADe/CADx CADx CALD CALR gene CAMP4 CAN10 CAP-002 CAPItello-280 CAPS-5 CAR T-cell CAR-T engineering CAR-iNKT cells CARDINAL study CARIS Life Sciences CARsgen Therapeutics CB1 inhibitor CBB-120 CBC Group CBI-1214 CBX-250 CBX-663 CD CD19/CD20 CD20 Antigens CD20-directed therapy CD3 T cell CD38 Antigen CD38-directed antibody CD4 + T-cell CD4 + T-cells CD47 Antigen CD8 T cells CDC vaccine recommendation CDC7 protein, human CDH17 protein, human CDH6 gene CDK inhibitors CDK2/4 degrader CDK4 inhibitor CDK4/6 inhibitors CDMO/CRO CDMOs CDOO CDTO CE-IVD CEDAR study CELIA CEO Kai Beckmann CEO Luke CEO Mike CEO Thomas Schinecker CEO Ulf Hannelius CEO appointments CEO replacement CEO resignation CEPI CETP CFD-FOLR1 CHARM Therapeutics CHEK1 protein, human CHORD trial CHRS CHW Access Act CIAS CIDP CAPTIVATE trial CIHR CITY-FXI CITY-RBP4 CLD-423 CLIA CLIA-waiver CLL-314 CLL/SLL CLUS CMO appointment CMS CMS Interoperability Framework CMT-SORD CNS activity CNS drug development CNS pipeline CNS-3D CNS-penetrant COINS Act COM503 COM701 COMPOSE trial COO CORALreef Lipids CORALreef trial CORDStrom CPI-refractory tumors CPO CR-001 CRB-701 CRBN gene CREM gene CRISPR CRISPR gene editing CRISPR therapies CRISPR therapy CROI CROSSJECT CROs CRPS-1 CSL-Behring CSNK1E gene CSP2026 CT-132 CT-155 CT-388 CT-868 CT-P72 CTAD CTMS CTMX CTPS1 inhibitor CTX310 CUE-501 CV features CX-2051 CXCR4 gene CYPRESS study Cabaletta Cabaletta Bio Cabometyx CagriSema Wegovy Calcified (qualifier) Caldera Therapeutics Calico Califf California residents Calley Means Calquence Calypso study Cambridge Massachusetts Cambridge research labs Camilla Harder Hartvig Camilla Sylvest Camurus Canadian Canadian Cancer Society Canal Row Advisors Cancer Diagnosis Cancer Drug Sales Cancer Prevention Cancer Research Institute Cancer Risk Cancer Survival Candel Candid Therapeutics Cannes Cantargia Cantor CapVest Partners Capability Capital Expenditures Capital Markets Capitol Hill Capricor Capricor Deramiocel Caps Capsida Biotherapeutics Captain T Cell Carbapenems CarbonAI Carcinoma in Situ CardIQ Cardiac Arrhythmia Cardiac ablation Cardiac care Cardiac monitoring Cardiff University CardioMEMS Hero Cardiospermum grandiflorum Cardiothoracic surgery specialty Carduelis cannabina Caremark Caremark Rx Caris Detect Caris MI Carl Dugart Carl June Carlo Incerti Carlos Quezada-Ruiz Carole Ho Caroline Dorsa Cartography Catabolism CatalYm Catalyst Pharmaceuticals Catherine Bovenizer Cecile Guegan interim Celiac Disease Cell Culture Techniques Cell Differentiation process Cell Shuttle Cell Transplantation Cell-free protein CellDx-Tissue CellOPTIQ Cellares Celldex Cellular Origins Cellular Reprogramming Celtic Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Centers for Medicare and Medicaid Services Central Nervous System Agents Ceperognastat Cerberus Ventures Cerebral Adrenoleukodystrophy Cerebrotendinous Cereno Scientific Cevidoplenib Chad Chagas Disease Chai Discovery Chance Act Changchun GeneScience Pharmaceutical Change Management Charcot-Marie-Tooth Disease Charles Fuchs Charles Ryan Charles Weissmann ChatGPT Health Chaudhuri Chechen language Checkpoint Therapeutics Chemify Chemoradiotherapy Chemputation Cheryl Blanchard Cheryl Lubbert Chickenpox Vaccine Chief AI Officer Chief Clinical Officer Chief Development Officer Chief Digital Chief Health Officer Chief Marketing Officer Chief Quality Officer Chief Revenue Officer Chief Science Officer Chief Scientific Officer Chief Strategy Officer Chiesi Group Children Program Chimera organism Chimerix Chimerix acquisition China 's China approval China legal issues resolution China pharma China trial China-Derived Drug China-sourced asset Chinese Neurosurgical Journal Chinese study Cholangiocarcinoma Cholesterol Drug Cholinergic Receptors Chondrosarcoma Chordoma Chorea Chris Barry Chris Boerner Chris Lance Chris Shibutani Christiane Bardroff Christopher Martin Christopher Viehbacher Chromatography Chromosome 7 Short Arm Chronic Care Management Chronic Condition Chronic Inducible Urticaria Chronic Inflammatory Demyelinating Chronic Obstructive Airway Disease Chronic cough Chronic granulomatous disease Chronic heart failure Chronic lung disease Cigna Cigna 's Ciliary Neurotrophic Factor CinCor Pharma Cingulate Circuit Cirrus Citation City Therapeutics Civil Rights Act Clarametyx Biosciences Clarity Claros facility Class Class 1 resubmission Class A Class II Medical Device Classical galactosemia Claude Allary Claude Science Claudin 18.2 ADC ClearStrand-ASD Clearmind Medicine Clesrovimab CliCr Click Therapeutics ClinVar CliniQuantum Clinical Decision-Making Clinical Deployment Clinical Equipoise Clinical Evaluations Clinical Relevance Clinical Setback Clinical Trial Suspension Clinical Trial Termination Clinical pharmacology discipline ClinicalTrials.gov CloakLink linker technology Cloning Vectors Closed Loop Medicine Clyde Biosciences Clywedog Therapeutics Co-Diagnostics Co-Dx PCR platform Coartem Cochrane review Coefficient Bio Cognition Therapeutics Cognitive Cognitive function: initiation Cognitive function: planning Coherus Oncology Cohort Coinbase Coleman Colin Murdoch Collegium Collegium Pharmaceutical Colonic Polyps Comac Combined immunodeficiency disease Comirnaty Commerce Commercial Officer Commission approval Committee Communications Media Community Clinical Oncology Program Community Health Workers Comorbidity Comparative Genomics Comparison Compass Compassionate Use Compensation Committee Complement Membrane Attack Complex Complex Complex Regional Pain Syndromes Compound MOA Compugen Computational Biology Computer Security Concentra Concern Concurrent Condition Congenital Cytomegalovirus Infection Congenital deafness Congenital disorder of glycosylation type 1A Congenital emphysema Congress reauthorization Congressional Hearings Connect (action) Connecticut biotech Connectivity Constellation platform Constitutional Challenges Consumer Consumer Behavior Continuance of life Continuous Delivery Contraceptive Implant Contraceptive methods Contract Development Contrave Controlled release Convenient CorMedix Corbus Pharmaceuticals Corcept Therapeutics' Core CorestemChemon Corneal epithelial defect Cornerstone Robotics Cornucopian Capital Corporate Update Correspondence as Topic Corsera Health Corstasis Corvus Corvus Pharmaceuticals Corxel Pharmaceuticals Cosette Pharmaceuticals Cost Control Cost Plus Drugs Cost savings programs Counsel Health Court of Chancery Covalent Interaction Coya Therapeutics CpcPH Craig Crews Cranial Navigation platform Craniodiaphyseal dysplasia Craving for alcohol Create Medicines Creatine Kinase Crescent Biopharma Creyon Criminal Justice Crinetics Crisis Cristal Therapeutics CrossBridge Bio Crossbow Therapeutics Crown Bioscience Cryptigen CryptoMap platform Crystalys Therapeutics Ctexli Cu-Zn Superoxide Dismutase Cues Curapath Cure (remedy) CureVac acquisition Curevo Curevo Vaccine Curium Pharma Curon Biopharmaceutical Curve Biosciences Cushing 's syndrome Cutaneous sarcoidosis Cyclerion Therapeutics Cyclic GMP Cyclin-Dependent Kinases Cylinder Health Cynata Cyprium Therapeutics Cyprumed Cytek Biosciences Cytokine Release Syndrome Cytology diagnosis Cytomegalovirus Infections DARPA-funded initiative * * DAWN DAZALS trial DCD gene DCT gene DDX11-AS1 gene DECODE DESTINY-CRC02 DESTINY-Lung01 DESTINY-PanTumor02 DFO DFTX DIA AI Consortium DIAGNODE-3 DLBCL-1 DLL3 DLL3-targeting therapy DMC DMR-001 DNA Methylation DNA Repair DNA Sequence DNA Sequence Rearrangement DNA-damage response DNDi DNL593 DNTH DNTH212 DOGE 's DPP1 inhibitor DREAMM DREAMM-8 DSC3 gene DSO DT-101 DT-216P2 DT-9081 DTC Campaign DTX301 DURAVYU DURECT DURGA-1 DXCM DYNAMIKA DYNE-251 Daiichi oncology Damon Lanphear Dana-Farber Danish pharma Danyelza Dark Blue Therapeutics Dark color Darpa DartsBio Darwazah Dasynoc Data Analytics Data Fidelity Data Lakes Data Management Data Release Data Science Data-Driven AI Databricks Datar Cancer Genetics Datroway breast cancer Dave Denton David Guyer David McGuire David Meek David Schenkein Day 2 Daymark Health DePuy Synthes Deal Flow Deal Structure Decanoates Decatur Illinois December 2025 Deciparticle nanomedicine platform Deciphera acquisition Decnupaz Deep Brain Stimulation Deep Learning DeepMind DeepSearch DeepSeq DeepView System Deerfield Degenerative polyarthritis Degrader-Antibody Conjugates Degree or extent Degrons Del-zota Demand (clinical) Dementia Research Institute Demis Democrats Denifanstat Denmark Dennis Dean Dental Solutions Denton Department of Justice Departure - action Depemokimab Deraphan Dermatographic urticaria Dermis Derrick C. Li ; Chief Business Officer Desiccation Desire for food Desiree Cain Deutsche Bank Develop Developing Developmental (qualifier value) DeviceGuide Dexcom G7 Dexpramipexole Diabetes Therapy Diabetic Nephropathy Diabetic monitoring - injection sites Diagnostic Accuracy Diamond Therapeutics Diamyd Medical Diastasis Diet, High-Protein Difficult-to-Express Proteins Diffuse Glioma Digital Technology Digital Trial Digital X-ray Digital digestive health Digital innovation Digital therapeutics Digital tool Dilution technique Dimitri Azar Diorasis Diphosphonates Diphtheria-Tetanus-Pertussis Vaccine Direct-to-Consumer Advertising Directed share Disability Disasters Disc Medicine Discipline of Nuclear Medicine Disclosure Disease Evidence Principles Dispatch Bio Disputes Dizal Doctronic AI system Donanemab Dong-E-E-Jiao Donna Haire DopApp Dopamine D2 Receptor Dorsal Dose-Limiting Doustdar DoveTree Medicines Dr. Gavin Dawe Dr. Sara Brenner Draig Dren Bio Drug Compounding Drug Development Tool Drug Evaluation, Preclinical Drug Kinetics Drug Negotiation Program Drug Overdose Drug Pricing Program Drug Repositioning Drug development costs Drug licensing Drug packaging industry Dry AMD Dual-chamber systems Duato Duet, Prenatal Multivitamins Duke Clinical Research Institute Dukoral Dupixent-in-a-pill Duvakitug Dyggve-Melchior-Clausen syndrome Dynamic Shared Ownership Dynavax Dyno Therapeutics E-688 E-Scopics E. coli disease E100 survey E6(R3 EB613 ECG-AI ECLIPSE program ECT EDIT-401 EDNRA gene EFS gene EHA Congress EIK1005 EKF Diagnostics ELEVATE-44 ELP Technology ELSC ELT ELV001 ELVN EMA Approval EMA China EMBARK EMBER-3 trial EMERALD-3 EMPEROR EMPEROR Phase III trial ENCELTO ENT1 ENV-294 ENaBL Platform EO-1022 EO-3021 EOC EOS-215 EOS-984 EP'949 EP4 Antagonist ONO-4578 EP4 antagonist EP4 receptor antagonist EPCAM gene EPCORE EPKINLY EPRAD ER-100 ER-Positive HER2-Negative Breast Cancer ERAS-0015 ES-SCLC ESC25 ESGO ESK-001 ESMO IO ESO-T01 ESSDAI ETA EU AI Act health EU Approval EUA EVO301 EVO756 EVOKE trial EVOKE-03 trial EVOQ EXCALIBER-RRMM EXHALE-4 EY Early Intervention (Education) Early-Stage Pipeline East Asian American East Asian Americans East Windsor facility Ebglyss Ecnoglutide Economic Conditions Economic Growth Economic Investment Committee Edap Edenbridge Edge AI Edison Oncology Edison Scientific Editas Medicine Edotreotide Education, Medical Edward Conner Efluelda Efruxifermin Eftilagimod alfa Eight Ekterly Elasticity Imaging Techniques Election Proposal Electrocardiogram Electrocardiography, 12-Lead Electroconvulsive Therapy Electroencephalography Electromechanical dissociation Electronic Electronic Health Records Electroporation Eledon Elektrofi ElevAAte Elevara Medicines Eli Lilly & Co. Eli Lilly ; Novo Nordisk Eli Lilly David Ricks Eli Lilly acquisition Eli Lilly competition Elinzanetant Elix Elizabeth Montgomery Elkridge facility Ella Platform Eloralintide Elrexfio Elsa Emblaveo Emergency Situation Emergency Use Authorization Emergency department patient visit Emergent BioSolutions Emi-Le Emirati Genome Program Empower Pharmacy Empowered Empress Emrelis Enanta Enbrel Enbumyst Encapsulated (qualifier value) Encephalitis Encephalitis, St. Louis Encephalopathies Encryption End Point Endogenous Eneboparatide England Enh3ance trial Enki generative AI Enlaza Enrollment Entera Bio Enterome Enterprise Entity Entrada Therapeutics ' Entyvio Environmental pool Enzeevu Enzyme Replacement Therapy Enzyme Therapy Eosinophilic esophagitis EpiVax Epicrispr Epicrispr Biotechnologies Epidemic Epidemic Preparedness Innovations Epigenic Epilepsies, Partial Epiminder Epitopea Equillium Equipment Equipment and supply inventories Erelzi Erica Palsis Erica Taylor Erik Atkisson Erika Porcelli Erleada Erleada apalutamide Erleada upstream data ASCO Erythropoietic Protoporphyria Escalation Eshkenazi EsoBiotec Esophageal Neoplasms Essential Tremor Ester Banque Esthetics (discipline) Estimated Estrogen receptor positive Ethics Ethics Committees Ethyreal Bio Etiome Eua (gastropod) Eucalyptus Eukaryotic Cells Europe market European Group for Blood and Marrow Transplantation risk score (assessment scale) European Hematology Association European Medicines Agency European Union Evaluate report Evan Rachlin Everest Everest Medicines Everlywell Evfraxy Evidenced Evidity Health Capital Evommune Evopoint Biosciences Evorpacept Evrysdi Ewings sarcoma Ex-FDA ExPEC9V Exact brand biomedical or dental material Excalipoint Therapeutics Excellergy Exciva Executive Board Executive Board Changes Executive Leadership Team Executive Order 14273 Executive Team Change Executive Vice President Exercise Exfoliation Syndrome Exit activity Exl-111 Exon Skipping Exons Expanding Expedition Medicines Experience Experimental drug Expert Systems Expiration Exposome Extencilline External Director External Ventricular Drain Eye Drops Eye safety EyePoint EyePoint Pharmaceuticals Eyebrow structure Eyelash Eylea biosimilar FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 FAERS FAK/ALK/ROS1 Inhibitor APG-2449 FALKON FDA-approved therapies FDA-cleared AI FDA/EMA regulatory pathways FDR FGFR1 gene FGFR3 inhibitor FIGHT China Act FILSPARI FINDER FINEARTS-HF FL-501 FOG-001 FORTE FORTIFY FORTITUDE-101 FORTITUDE-102 FOXD3 gene FREEDOM2 FSP FUJIFILM Biotechnologies FUROSCIX FXR314 FXS6837 FY2026 Facilities Association Facioscapulohumeral Factor XI antibody Factor XIa inhibitor Factory Faeth Family Fringillidae (organism) Family suidae Fanconi Anemia Farapulse Faro Faron Pharmaceuticals Fasenra Faslodex Fast Track designation Favorable Favored Favored Nation Fear (Mental Process) Febrile Convulsions Federal Appeals Court Federal reduction-in-force statute Federated AI Feeling content Fees Fellows Ferring Ferring Pharmaceuticals Fertility Fetal Hemoglobin Fetal and neonatal alloimmune thrombocytopenia Fetroja Fetus FibroBiologics FibroGen 's Fibroblast Therapy Fibromatosis Fibrosis Fibrosis, Liver Field Medical Fill/finish Filspari Finance Financial Stress Financial Times Findable Fine - adjective Firefly Bio Firelink platform First-in-Human Clinical Trial First-in-Human Study Fiscal 2026 Flare platform Flatiron Health Flexible Flow Flow Cytometry FlowMod Flu A/B FluBlok Fluad FluidCrystal technology FluoGuide Fluzone Focal glomerulosclerosis FogPharma Food Allergy Food Policy Food, Processed For which was done Forced Vital Capacity Forma buyout Formal Dispute Resolution ( Format (qualifier value) Formation Bio Formula - diet Fortrea FoundationOne CDx FoundationOne Genomic Profiling Foundations Founders Fund Fractyl Health Francis Francis Braun Francis Crick Institute Francis Wilson Frankfurt plant closure Frazier Life Sciences Free Mind ' Campaign Free Nurse Program ' FreeStyle Libre Fresenius Freshworks Friday Friedreich Ataxia Fujifilm Biotechnologies Fulcrum Therapeutics FulcrumSec Full-Life Functional improvement Fund I Fund III Fused structure Futility Analysis Future FutureTech II G12C inhibitors G12D inhibitor G3BP2 gene GABA A GABAergic interneurons GALA peptide GB-0895 GBS GCG GCG/GLP-1 agonist GDF8 protein, human GDUFA IV GE8820 GEMINI trial GEN1107 GH Research GH001 GHO Capital GI care GI oncology GJB2 gene therapy GLA GLM101 GLOW2 GLP-1 medications GLP-1 pipeline GLP-1 therapies GLP-1/GIP agonist GLP-1/GIP co-agonist GLP-1/GIP therapies GLP-1/GLP-2 GLP-1/glucagon GLP-1RA GLPG5101 GM-2505 GMMA platform GMP GMP violations GO29781 GPC3 protein, human GPCR pipeline GPCRs GPR182 gene GPT-5.2 GRADUAL-3 GRAS GRAS Reform GRT-001 GS-0321 GS-098 GS/pan-Notch Inhibitor AL101 GSBR-1290 GSK 's GSK Emma Walmsley GSK Spero GT Medical Technologies GT801 GTPase-Activating Proteins GUB014295 GUBamy GUTC GXO Gabriel Baertschi GalNAc Galafold Galapagos layoffs Galatea Bio Galaxies Galaxy Brain Scientific Galderma Galecto Galera Therapeutics Galleri Galleri test Galux Gambling Gamma/Delta T-Lymphocyte GammaTile Gan & Lee Pharmaceuticals Garda Therapeutics Gardasil sales Garetosmab Garijo Gastric Bypass Gastrointestinal Neoplasms Gastroparesis Gate Bioscience Gateway Labs Gaucher Disease Gavi Vaccine Gdańsk Gefion AI Supercomputer Gefurulimab GemPharmatech Gemini 3.1 Pro Gemini Enterprise GenEvolutioN GenSci GenScript Piscataway Pennington Gene Expression Profiling Gene Writing Gene-Edited Genelux Corporation Genentech Vice Presidents axed Genentech infectious disease General Data Protection Regulation Generalized pustular psoriasis Generate Generation Park Generations Generative Phosphoproteomics Genes Genesis Molecular AI Genetic Biomarkers Genetic Kidney Diseases Genetic Leap Genetic screening method Genetic testing for cancer risk Genetix Biotherapeutics Genevant Geno J. Germano Genomenon Genomic Orientation Genotype Genus Aviceda Genus Malus Genus: Coronavirus GeoVax Geoff Hamilton ; Chief Financial Officer Geographic Intersection Geographic Locations German language Geron Geron Corporation Gestures Giant Cell Arteritis Giant Cell Tumors Gilde Gilead Merck HIV Gilgamesh Gitte Pugholm Aabo GlaxoSmithKline Glenmark Glenn Coleman Glickman Glioma Global Biobank Global Health Global Restructuring Global commercial operations Globalisation Globalization Glucagon-Like Peptide 2 GlycoEra Glycomine Golden Triangle Good Machine Learning Practice Google Google Play Store Gordon Gossamer Bio Gossypium Gout GovEvents Government Shutdown Grabody-B Grace Niu Grade five rank Gram-negative infections GramEye Grand Prix Graphene Graves Disease Gray Delany Great Healthcare Plan Greater China Region Greenoaks Gregory Verdine Grin Gross margin Groupe Bruxelles Lambert Growth Differentiation Factor 15 Growth Hormone Grünenthal Guardant Health Gubra Ventures Guggenheim Securities Guidance 2024 Guillain-Barre Syndrome Guillain-Barré syndrome Gumokimab Gurunathan Gut-Brain Health GxP Gyre stock H. Martin Seidel , H2H trial H5 avian influenza H5 bird flu HAELO HCM HCP HDV RNA HER2- HER2-low HER2-low breast cancer HER2-positive metastatic breast cancer HER2-targeted therapy HER2-targeting antibody drug conjugate HER2-ultralow HER2CLIMB-05 HER3 HERCULES trial HERO trial HFmrEF HH160 HHS Overhaul HIF-2a HIV franchise HKEX HLFM HLX07 HLX701 HM15912 HNGE HOOKIPA HOPE-2 trial HPP HR-positive/HER2-negative breast cancer HRR gene mutation HRS-9821 HS-001 HS-20094 HS-20110 HSCT HSE HSP90 Heat-Shock Proteins HSV-1 viral vector HTGS26 HTS HU6 Haduvio Hahn Hair Analysis Hairy Cell Leukemia Haleon demerger Halle Halo brace Halozyme Therapeutics Hamed Khalili Hand Strength Hanmi Pharmaceuticals Hans Henrik Chrois Christensen Hansoh Hansoh Pharma Hansoh Pharmaceutical Hansoh Pharmaceuticals Hantavirus Harbinger Harbour Mice technology Harbour Mice ® technology Harmony Biosciences Harout Harris Lazarre Harvard Research Harvard University Hassabis Hatteras Hatteras Opportunity Fund I Hatteras Venture Fund VII Haya Hazard Ratio HeFH Head of Growth Head of Non-Clinical Development Head of Strategy Health & Wellness Health Canada Health Care Sector Health Care Systems Health Data Innovations Health Data Research Service Health Data Research UK Health Equity Health Improvement Health Information Systems Health Insurance Portability and Accountability Act Health Radar Health Services Research Health Services, National Health Systems Agencies Health Workforce Health conditions:-:Point in time:^Patient:- Health education HealthCare Royalty Healthcare Payers Healthcare services Healthy America Heart-2 Heather Knight Helen Jones Helicon Helicon peptides Helicore Helix (Snails) Hematological Disease Hemgenix Hemlibra Hemophagocytic Hemophilia B Hepatitis Delta Virus Hepatitis, Alcoholic Hepatoscope Hepcludex Hereditary Diffuse Leukoencephalopathy with Spheroids Hereditary pancreatitis Hermanski-Pudlak Syndrome Hernexeos Herpes NOS Herpes Simplex Infections Hers Heterogeneity Heterotopic Ossification Hetronifly Hickory trial Hidradenitis High Drop-Out Rate High dose High-Frequency Microsatellite Instability Highest Hikal Hikma HilleVax Hillhouse Capital Hinge Health Hiroyuki Sonoda HistoSonics exit Histone deacetylase inhibitor Histopathological aspects Hizentra Hoist device Holistic epilepsy management Holter Electrocardiography Home Use Honeymoon Effect Hong Hong Kong IPO Hongjiang Miao Hookipa Pharma Horizon Hormone replacement therapy Hospital admission Hospital specialist Houman Ashrafian Hour House Appropriations Committee Houston Huahui Health Human Factors Human Glandular Kallikrein 2 Human Life Foundation Human Longevity Program Human Services Secretary Humanitarian Exemptions Humira patent expiration Hungary Huntington Disease Hyaluronic Acid anchoring platform Hybrid AI Hybrid Care Model Hybridopa Hypercon Hyperinsulinism Hypertrophic cardiomyopathy without obstruction Hypochondroplasia (disorder) Hypocupremia Hypoglycemia Hypophosphatasia Hypothalamic structure Høiland I CAN trial IB6 IBC IBI363 IBTROZI ICANS ICER ICR Fort Lee ICU ICU bedside procedures ICU nursing shortages IDE034 IDEAYA IDEAYA Biosciences IDO1 IDS gene IDWeek IDeate-Lung01 IGA IGC IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001 IGF1R gene IGNYTE IGYNTE IHC IL-13 antibody IL-17A monoclonal antibody IL-2 pathway IL-22 antibody IL-23 receptor antagonist IL-31 receptor alpha IL13 gene IL1RAP antibodies IL1RAP protein, human IMC002 IMM2510/AXN-2510 IMNN-101 IMPACT trial IMVT IMforte trial IMvigor011 INAVO120 INBRAIN INBRX-101 IND-enabling studies INF904 INHBE INHBE gene INLIGHT INLIGHT trial INMB INNOVOTEX INOVIO INZ-701 INmune Bio IO Biotech IPG IPS test IQLIK IRAK3 gene IRAK4 gene ISAC ISB ISM-001 ISM4808 ISPPD ITK gene ITP Iambic Iban language Icebergs Ichnos Glenmark Identification (Psychology) Idvynso IgG4-RD IgG4-related disease IgM antibodies Igalmi IkT-001Pro Ilant Health Illicit Drug Public Policy Illumina Ventures ImCheck Therapeutics Image Analysis Group Imagio Imaging System Imdylltra Imjudo Imlunestrant Immunai Immune Activation Immunic ImmunoForge ImmunoGen acquisition ImmunoPrecise Antibodies Immunoassay method Immunocompromised Host Immunofoco Immunoglobulin M Immunoglobulins Immunopharma Immutep Impacts, Environmental Improved Improving (qualifier value) Imsidolimab Imunon Imvax In Vitro [Publication Type] Inadequate (qualifier) Incentives Inceptive Incheon Inclusion Incubated Independence India 's Indiana Indiana manufacturing Indianapolis Indication restriction Individualized Indivior Indolent Non-Hodgkin Lymphoma Infant, Newborn Infections of musculoskeletal system Infectious Canine Hepatitis Inference Infinity Bio Infinity Smart platform InflaRx Influence Ingram Inhalation Solution Inhaler Inhibikase Inhibikase Therapeutics Inhibitor Discovery Initiative Injury due to exposure to external cause Injury of cornea Inluriyo InnoCare Innovative Health Initiative Innovative Medicine Innovent Innoviva Inovio Pharmaceuticals Inozyme Insight Insilico Inspira Technologies Instill - dosing instruction imperative Instrument - device Insurance Premiums Intas Intellidrop Intent Biologics Intercept Pharmaceuticals Interdisciplinary Studies Interim report Interius BioTherapeutics Interleukin-2 Interleukin-23 Subunit p19 International Aspects International Drug Prices Interoperability Interoperable Interventional Urology Interventional procedure Interventional radiology Intervertebral Disc Degeneration Interview Intestinal Failure IntraBio IntraBio Ltd. Intranasal approach Intravascular Invasive aspergillosis Invest Europe Investigational Invivyd Iovance Biotherapeutics Iptacopan Ireland Irish healthcare Ironwood IsoDDE IsomAb Italy antitrust probe Biogen Italy health service Itvisma Ivory Ixchiq vaccine Ixiaro Ixo-vec Izervay J.P. Morgan JADE101 JAGX JAK/SYK inhibitor JAK1/TYK2 inhibitor JAM JAMA study JBIO JC Virus JCV JN.1-lineage JNJ JNJ-2113 JNJ-4804 JPM Healthcare Conference JPMHC JPY JS005 JSPR JUST-AAV Jack Phillips Jacobio Pharma Jacqueline Corrigan-Curay Jade Biosciences Jaguar Gene Therapy Jaguar Health Jake Leach Jake Van Naarden James Jamie Jamila Jan Hillson Janssen Vaccines January 2026 Janus kinase 1 Janus kinase 2 Janus kinase inhibitor Januvia Jascayd Jason Litten Jasper Therapeutics Jeavons syndrome Jeff Knight Jeffrey Venstrom Jeito Jeito II Jeremy Levin Jeremy Shefner Jerome Jersey pharma Jersey site Jesper Jian Jiangsu Hengrui Jigani Facility Jim Lang Jim O'Neill Jiwan Joaquin Job Development Jodi Ungrodt Joe Rogan Joe Willey John Carroll Johnson & Johnson Intra-Cellular Johnson Joaquin Duato Joint Atomic Model Joint Ventures Jonathan Arambula Jonathan Vigdorchik Jonmark Jorge Bartolome Julie Kim July Juncos June June 11 June 18 2026 June 2026 June 4 Junshi Justice Jackson Juvenile K Pro KARD KARDIA-3 KARDINAL trial KAT5 wt Allele KAT6A degrader KB801 KCNT1 gene KER-0193 KEYNOTE-671 KEYNOTE-689 trial KEYNOTE-B96 KEYNOTE-B96 trial KINECT-DCP KIR-CAR KIT KKR KLKB1 gene KMT2A gene KOASTAL-2 KOASTAL-3 KOL Insight HR+/HER2- KOL Insight Psoriatic Arthritis KOMET-017 KP.2 strain KPI-012 KQ Labs KRAS KRAS NP_004976.2:p.G12C KRAS inhibitor KRAS-driven tumors KRAS-mutant cancers Kaerus KaiSR Kainova Therapeutics Kakao Healthcare Kaken Kala Bio Kane Biotech Kankakee Illinois Kansas City cardiomyopathy questionnaire Kaposi 's sarcoma Kappa-Opioid Receptor Karen Massey Karen Smith Karim Mikhail Karin Conde-Knape Kashiv BioSciences Kate Estep Kate Walsh Katherine Szarama Keir Starmer Keith Keith Vendola Ken Paxton Ken Song Kendall Square Kennedy 's Kenneth W. O’Keefe Keren Leshem Kerry Dailey Kestrel Kevin Hardage Kevin Lobo Keystone Symposia Keytruda Qlex Keytruda SC Keytruda bladder cancer Keytruda combo Keytruda combo kidney cancer Keytruda head-to-head trial Keytruda patent Khalid Nabilsi Kidney Kidney Failure Kidney Failure, Acute Kidney Failure, Chronic Kim Kin-Hung Peony Yu Kinase Assay Kits Kinaset Kinevant Kit device Kite Pharma partnership Kite, device (physical object) Klaas Zuideveld Kleiner Knee pain Kodiak Sciences Komodo Health Kong Kong stock exchange Korea Korean language Kosmos Kostaive Kowa Krazati Kristin Bittenbender Kriya Kronos Kronos Bio Krystal Biotech Kumquat Biosciences Kura Oncology Kv7 activator Kyle Diamantas Kyle LaHucik Kymab Kymera Therapeutics Kyntra Bio Kyverna Therapeutics LAG-3 immunotherapy LAGOON trial LAPSCOVERY LAVA-1266 LBP LDLR gene LEAD platform LEAP District LEAP2MONO LENZ LFMD LGBTQ+ professionals LGMD2I/R9 LIGAND-AI LITESPARK-022 trial LLM-based technology LLMs LMT15 LNTH-2501 LONP1 gene LOTIS-5 LOTIS-7 LP.8.1 sublineage LR-MDS LRP4 gene LRPAP1 gene LRRK2 gene LTBR agonist LUCE-1 LUNA 3 trial LX9851 LaNova Medicines Labor (Childbirth) Labor Unions Lancet Landscapes Lansing Michigan Lantheus Lantheus Holdings Larix Lark Health LarkVantage Lars Rebien Sørensen Larsucosterol Latex Fixation Tests Latigo Latozinemab Launch-HTN Laverock Therapeutics Lawrenceville Leaders resign Leaked Lean Derisking Leapfrog Bio Lebanon Leber congenital amaurosis-4 Left atrial pressure Left ventricular ejection fraction Legal Case Legal Challenges Legend Biotech Somerset Raritan Lehigh Valley Lens platform LensAI Lenvima Lepodisiran Lesion Lesion reduction Letitia James Leukoencephalopathy, Progressive Multifocal Lewy bodies Libertas Bio Libertyville Illinois License Agreement Life Life Biosciences LifeMine LifeSignals LifeX Lifespan Extension Lifetech Lifyorli Ligand Pharmaceuticals Light AI Ligufalimab Lilly 's Lilly Jaypirca pirtobrutinib Lilly Novo Nordisk Lilly Verve buyout PCSK9 therapy Lilly inks Lilly obesity Lilly oncology chief Limitation Limited stage (cancer stage) LimmaTech Linac QA LinusBio Lionel Seltz Lipid Metabolism Disorders Lipids Lipoidosis Lipomatosis, Multiple Symmetrical Lipoprotein(a ) Liposarcoma, Dedifferentiated Liquid CDx Lisa Eli List Litespark Lithotripsy Livdelzi Live - Specimen Condition Live Biotherapeutic Product Liver Cirrhosis Liver damage Loan Logica London Bioscience Innovation Centre London Cancer Long-Term Strategy Longwood Fund Lorbrena Lorundrostat Losers Lotte Lower Profile Lower Rates Lp(a ) drug Lukas Braunschweiler Lukácsháza Luma <eudicots> Luma Health Lumakras Lumina 3D Lumryz Lumvoa FDA LunAIRo Lung Diseases, Interstitial Lung consolidation Lung-201 Lunit Lunit AI Lunit SCOPE Lunsekimig Lunsumio-Polivy Lupinus Lupus treatment Lutathera Lutetium-177 Lyell Immunopharma Lyfgenia Lymphatic Abnormalities Lymphocyte Count measurement Lymphocytes Lymphocytes, Tumor-Infiltrating Lymphohistiocytosis Lynavoy Lynk Lynozyfic Lyophilized Inactivated Group A Streptococcus TARA-002 Lysergic Acid Diethylamide Lysosomal Storage Diseases M Ventures M financing M growth fund M&A consolidation M&A surge M&A transactions M-TEER M.D. M6495 M9466 MACE-3 MAGNITUDE-2 MASLD MATTERHORN trial MC4R MDASE MDD MDM2 Antagonist ASTX295 MDM2 gene MDNA11 MDNA113 MDR MDR CE Mark MEERKAT trial MEK inhibitor MESA MET exon 14 skipping mutation MET protein MFLUSIVA MGI MGnify Stability Dataset MIPOGA MIPSA technology MIRACLE trial MIT MITIGATE trial MK-7240 MLTX MMRV vaccine MOG antibody disease MONARCH-E MPS MR closure MR-139 MRCT MRD MRD-negative MRM Health MS MS drug MSH5 gene MST brand of morphine sulfate MST-0312 MTLE MTX240 MVM MWT MYB transcription factor MYO7A gene MYR301 MZE829 MaGic trial MacTel Macao Machado-Joseph Disease Machine Macular degeneration Macular retinal edema Madness Madrigal Magnet <device> Magnetic Seizure Therapy MagnetisMM-5 Magnetocardiography Mahery Mainland China Maintenance study Maker (occupation) Malignant Bone Neoplasm Malignant Female Reproductive System Neoplasm Malignant neoplasm of cardioesophageal junction of stomach Malignant neoplasm of thyroid Malus domestica Management procedure Manfidokimab Manifold Bio Manihot esculenta MannKind Mantelli Manufactured Supplies Manufacturer Manufacturing costs Marcel Reichen Marco Rubio Marengo Maria C. Freire Marietta Pennsylvania Marjan Farid Mark McLellan Mark Pavao Mark Stevenson Mark Turco Markers (device) Marketing Martes pennanti Martin Martin Makary Mary-Elizabeth MassBio Massachusetts biotech Mastermind Platform Mastocytosis, Systemic Matchpoint Therapeutics Maternal Health Matt Buckham Matt Skelton May 18 May 2026 May 26 Mayne Mayo Clinic Mazdutide Measurement Measuring ruler, device Mechanism (attribute) MedQA MedSurg MediKarma MediView MediView XR MediView XR90 Medicaid block grants Medicaid fraud Medical Advisory Board Medical Affairs Medical Communications Medical Imaging Medical Records Medical pathologist Medicare coverage Medicare drug prices Medicare fraud Medicare reforms Medicenna Medicines Australia Medicines Discovery Catapult Medicus Pharma MedisourceRx Medivis Medline Medtronic Megadeals Megarounds Meister Melanie Ivarsson Melanoma TRP2 CTL Epitope Vaccine SCIB1 Membranous glomerulonephritis Memo Therapeutics MenABCWY Menopausal symptom Menstruation Mental association Mentorships Merck 's Merck Verona Mereo BioPharma Mersana Metagenomi Metals Metapneumovirus Metastatic Prostate Carcinoma Metastatic to Metis people Metric (substance) Michael Bierl Michael Burgess Michael Chou Michael Houghton Michael Kott Michael Langer Michael Rogers Microarray Analysis Microbial Microbiome SER-155 Microbiome therapeutics Microbiome-derived Peptide Vaccine EO2463 Micron Biomedical Microsoft Discovery Microsoft Teams Microvillus inclusion disease Miels Mikael Mikael Dolsten Mikaela Naylon Give Kids a Mike Hershkovitz Mike Sciandra Mike Stuart Mild cognitive disorder Miltenyi Biopharma MindWalk Holdings Corp. Minder system Mindpeak MinervaX MingMed Biotechnology Minghui Minimal Residual Disease Negativity Ministry of Health Mint - sweet Minxiang Zeng Mirum Mirum Pharmaceuticals Misleading Drug Ads Mismatch Repair Deficiency Missing Mitchel Berger Mitigation Strategy Mitochondrial Diseases Mitral valvuloplasty Mitsubishi Mitsubishi Tanabe Pharma MoSEIC Mobile Health Mochida Pharmaceutical Modeling Moderna vaccine facilities Modernization Modeyso Modic Mohammed Moist Molecular Clamp technology Molecular Gates Molecular Imaging Molecular Targets Moleculin Monarez Monte Montes Montgomery County Month of May MoonLake Immunotherapeutics Morbidity - disease rate Morgan Stanley Morristown Motion Mourenx Movantik Move GBS Forward™ Movement Mucopolysaccharidosis I Mucopolysaccharidosis III Multi-Drug Resistance Multiomics Mumps Mundipharma Munich Regional Court Mural Mural Oncology Muscarinic Agonists Muscle Tissue Muscle strain Muscle-Boosting Drugs Musk MyHealth app MyLabcorp MyOme MyPhenome Mycobacterium tuberculosis Myelin Sheath Myeloid Progenitor Cells MyoKardia Myocardial Infarction Myositis NAION NBI-1070770 NDA filing NEO100 NEPTUNUS-1 NEPTUNUS-2 NFX NGAL NGM NGN-401 NGS NHS NHS England NHS trial NHS-Galleri trial NIH grant NIH layoffs NIH-funded NINL gene NIO NK1/NK3 receptors NKTX NLRP3 inhibitor NMPA NON Mouse NOVI NP-MP1 NPDR NPM1 gene NPM1-mutant NR1H4 gene NR4A2 gene NRG NRG1 gene NRTX-1001 NSCEB NTHI NTLA-2002 NUCLIDIUM NUSAP1 gene NUZ-001 NVG-291 NVIDIA 's NVIDIA Lilly NX-3911 Nabla Bio Nach01 Namandjé Bumpus NanoDisc NanoPhoria Nanobody Discovery Platform Nanomedicine Nanostructured Materials Naphthoquinones Nasal Polyps Nasal drug delivery Nasal inflammation Nasdaq Stockholm Nasua Natalia Misciattelli Natera National Association of National Biotechnology Conference National Cancer Institute National Priority Vouchers National Resilience National Security Commission Natural killer triggering receptor, human Nature Nature Aging Nature Biotechnology AI biology Nature Biotechnology Nanovials Nature Biotechnology billion Nature Biotechnology cell-cell interaction Nature Medicine Nav1.8 inhibitors NeOnc Technologies Nebulizers Negative Negative Predictive Value of Diagnostic Test Negotiation Program Neko Health Nektar Nelson Sun ; Chief Operating Officer Nemluvio Nemvaleukin Alfa Neo-1 Neoantigen Neomorph Neumora Therapeutics NeuraClick Neural Circuit Stimulation Neural Network Simulation NeuralPLexer Neurimmune Neuro Disease NeuroThera Labs Neurogene Neuromuscular Monitoring Neuromyelitis Optica Neurona Therapeutics Neuropsychology Neurosteroids Neurostimulation procedures of spinal cord tissue Neurotrophic keratitis Nevada Nevada <Geographic Area> New Approach New Approach Methodologies New Jersey operations New York AG New York Stock Exchange NewAmsterdam NewBridge Pharmaceuticals Newborn NewcelX Nexon platform Nexplanon Next Pathways NextCure NextGen NextRNA Nextstellis NiKang Therapeutics Nia Tatsis Nick Eshkenazi Nick Vatakis Nicole Ossey Nicole Verdun Nimacimab Nimble Nimbus Niowave Nipocalimab Nippon Shinyaku Nominee Non-Hormonal Non-Incretin Non-Muscle Non-Opioid Non-Opioid Pain Nona Biosciences Nonalcoholic Steatohepatitis Noninvasive Endpoint Noom Nordisk alliance Nordisk facility Norovirus North Chicago North Chicago Illinois North Star Ambulatory Assessment Clinical Classification Nosis Novartis ' Vasant Narasimhan Novartis Venture Fund Novartis-Chinook acquisition November 2025 Novo Holdings Novo Nordisk Plainboro NovoCare Novocure Nubeqa Nucleus RadioPharma Nulibry Numab Numerous Nura Bio Nutrition Guidelines Nuvalent buyout Nuvation Nuvation Bio Nuzolvence OASIS poly(divinyl-co-N-vinylpyrrolidinone) OBT OBX-115 OCT50 OCU400 OCU410 OFA OHSU OIG bulletin OKYO OM336 OMass ONS-5010 ONWARD OPKO OPTIMA trial ORKA-001 ORN-252 ORNITHINE CARBAMOYLTRANSFERASE ORX142 ORX489 OSE Immunotherapeutics OTX-201 OTX-TKI OX2R agonists OX40 agonist OX40 receptor OXPHOS pathway OXTR gene Oberon Obesity Drugs Obesity Trial Obsidian Therapeutics Ocaliva Occupational activity of managing finances Oceanside Ocedurenone Ocrevus October Ocugen Ocular Therapeutix OdyssION platform Officer David Rose Offit Ogilvy Health Ohtuvayre Omeros Corporation Omicron Omicron JN.1 Omnipod Omnitrope Omniverse On-Demand Events On-Demand Webinars Onapgo Once-Weekly Insulin OncoMimics Oncoinvent ASA Oncologic Oncology Collaboration Oncology Focus Oncology drugs Oncolytic Viruses Oncotelic Therapeutics OpenEvidence Operable Brain Tumors Operating Operating expenses Operation Trailblazer Operational streamlining Operative Surgical Procedures Operator Partners Opfolda Ophthalmological implant Opiate Addiction Opinions Opioid Opioid Crisis Opioid Use Disorder Opportunity Fund III Opthea Opthea 's Opthea layoffs Optigo Biotherapeutics OptimiZe technology Optimism Optinose Optogenetic Gene Therapy Opvee divestiture Oracle Health Oral Medication Oral Medicine Oral Wegovy Oral region Orals Orano Orbital Therapeutics Orca-T. Order Tubulidentata (organism) Organ Shortage Organisation for Economic Co-Operation and Development Organovo Ori-C101 Oricell Therapeutics Orion Group Orna Therapeutics Orotecan Orphan Cures Act Oruka Orum Therapeutics Oryon Cell Therapies Osanni Bio Oscotec Oslo Stock Exchange Osteogenesis Imperfecta Osteoporosis Ostro acquisition Otsuka 's Otsuka Holdings Otsuka Pharmaceutical Ottava Oura Genomics Oura Ring 5 Outfront Health Outlook Therapeutics Outlook Therapeutics ' Outsourcing Ovation.io Owkin Ownership Oxervate Oxford BioTherapeutics Oxford Finance Oxford spinout Oxycontin Oyster Point P-Value PACAP X CGRP bispecific PADOVA study PALSONIFY PB212 PBA PBC PBLS PC Platform PCED PCSK9 base PCVs PD-1xVEGF bispecific PD-L1-positive PD-L1xVEGF-A PDE3/4 inhibitor PDE4 inhibitor PDUFA VIII PER-001 PERIDOT PERSEUS trial PET/CT scan PF-06954522 PF-07872412 PF-ILDs PFAS gene PGI PGN-EDODM1 PHD inhibitor PI3 K inhibitors PI3 K pathway PIK3CA gene PIK3CA-driven PIK3CA-mutant PIK3CA/AKT1/PTEN pathway PIKTOR PIPE financing PIVOT-PO trial PKMYT1 protein, human PKP2-associated cardiomyopathy PMN310 POETYK PP353 PPF PRA023 PRC2 inhibitor PRECISE-AD trial PREVAIL trial PRISM BioLab PRMT5 gene PROGRESS-AD PROSERA PROTACs PRT13722 PRV PRX012 PSMA PSMA-targeting PTAB PTEN-deficient tumors PTH1R gene PTK7 PTK7 protein, human PTRS PURPOSE studies PYNNACLE trial Pacira Pacira BioSciences Pain Palleon Palvella Therapeutics Palynziq Pancreatic Ductal Adenocarcinoma Pandion Paolo Tarantino Papillary Disease Parabilis Paratek Parker Institute for Cancer Immunotherapy Parkinson Parkinson 's Paroxysmal nocturnal hemoglobinuria Part B drugs Participant Partner Therapeutics Partnering Partnering Office Pasadena Pascal Soriot Passage Bio Path-IO Patient Protection and Affordable Care Act Patient Square Capital Patient data Patient education (procedure) Patient location type - Department Patient-Centered Patrick Vink Patrizia Cavazzoni Patterns Paul Edick Paul Fornazzari Paul McKenzie Paul Thomas Paulo Fontoura Pavblu Payer Engagement Payspan Pazdur Peakbridge Pediatrics Pedro Beltran Peer-Reviewed Research Pelage Pelage Pharmaceuticals Pemgarda Pemphigus Vulgaris Pennsylvania site closure Pensions Pentagon Pentagon blacklist PepGen PepMetics Peptide Biosynthesis Perception Perianal fistula Peripheral Arterial Diseases Peripheral neuropathic pain Peripheral neuropathy due to and following antineoplastic therapy Perjeta Perkins Permanent Peroxisome Proliferator-Activated Receptors Persica Persistent Personality Character Perspective Perturb-seq Pet Animal Peter Greenleaf Peyronie 's disease Pfizer 's Pfizer Albert Bourla Pfizer Astellas Padcev Pfizer Ventures Pfizer acquisition Pfizer staff Pfizer vet Pfizer walk away Pfizer-BioNTech Phagocytosis Pharma Acquisition Pharma Concessions Pharma Manufacturing Pharma Tariffs Pharma import taxes Pharmaceutical Ingredients Reserve Pharmaceutical Layoffs Pharmaceutical Packaging Pharmaceutical Policy Pharmaceutical executive pay Pharmacogenomics Pharmatech Phase 1 - 2a Phase 1 Data Phase 1 trials Phase 1b/2 Trial Phase 1b/2a Phase 2 BEACON Phase 2 Failure Phase 2 HORIZON Phase 2 VALIANT Phase 2 data Phase 2 results Phase 2 termination Phase 2a Phase 2a Trial Phase 2b SYMMETRY Phase 2b trial Phase 3 Breast Cancer Trial Phase 3 COMPETE trial Phase 3 CREST trial Phase 3 HAELO Phase 3 INDIGO Phase 3 INDIGO trial Phase 3 PIVOT-PO trial Phase 3 RINGSIDE trial Phase 3 SENTRY trial Phase 3 SURPASS-IPF trial Phase 3 induction Phase 3 planning Phase 3 plans Phase 3 program Phase 3 prospects Phase 3 readiness Phase I – III study Phase I/II study Phase II Failure Phase II data Phase III AURORA trial Phase III Essence study Phase III MAGNITUDE trial Phase III MARIPOSA trial Phase III REGENCY trial Phase III ReSPECT trial Phase III ZENITH trial Phase III desmoid tumors Phenylketonurias Phesi Philip Brainin Phoenix Arizona Phosphodiesterase Type 4 Photoimmunotherapy Physical AI Physical Examination Physical activity Physician Executives PiNACLE Piclidenoson Pilatus Pill Penalty Pilot Pimurutamab Pinnacle Medicines Pioneer Antibody Discovery Pioneering Medicines Pipeline Review Pipeline Strategy Pitch - substance Pivotal Pivotal Trial Plants Plaque (lesion) Plasma Plenary Session Plenary Speakers Plexiform Neurofibroma Pliability Plozasiran Pluri Pneumococcal vaccine Poisons Pol Theta Polaryx Therapeutics Polivy Polpharma Biologics Polycythemia Polyradiculoneuropathy Pombiliti + Pooled Sample Portal Biotechnologies Portfolio diversification Positive Post-Exposure Prophylaxis Post-Pandemic Downsizing Post-bankruptcy consolidation Post-marketing study Poster Practice Experience Prasad 's Prasinezumab Pre-Clinical Model Pre-Consult Precision Pre-Exposure Prophylaxis Pre-filled Syringe Prealbumin Precision Diagnostics Precision Imaging Network PrecisionLife Predict Pregnanolone Prelude Therapeutics Premier Inc. Prescription Drug Overuse Prescription Fulfillment Presidential Symposium Preventive Health Programs Prevnar Primary Primary hyperoxaluria Primary sclerosing cholangitis Prion Diseases Priority Review Voucher Private Room Private financing Privigen ProFound Therapeutics ProMIS Neurosciences Proactive Health Probiotics Problem Probody Platform Professional guide Profiling (action) Profluent Progestins Projections Prometheus Prometheus Biosciences Promotional Claims Prompts Propel Prostate-Specific Antigen Prot-MaP Protara Therapeutics Protection Protein Kinase C Protein Kinase C Inhibitor Protein Purification Protein Stability Protein, Organized by Structure Protein-Protein Interaction Protillion Biosciences Proto-Oncogene Proteins c-akt Protoporphyrin IX Provider Provider Services Proximity Prurigo Pruritus PsA-2 trial PsCatCh2.0 Pseudobulbar affect PsiThera Psoriatic PsyLabs Psyence BioMed Public Health Trust Public Listing Puerto Rico Pulmonary Eosinophilia Pulmonary artery pressure Pulmonary veins Purchase Purchased Services, Clinical and Biomedical, Calibration, Laboratory Purchased Services, Clinical and Biomedical, Research Purchased Services, Staffing, Supply Chain Purdue PureTech PureTech Health Purpura, Thrombotic Thrombocytopenic Pushechnikov Put Option Agreement Pyelonephritis Pyoderma Gangrenosum Pyzchiva Q-Scientist Q1 trends Q126 Q2 layoff Q2 sales Q4 FY2025 QA QA102 QCS QIAsymphony QLS-111 QRS prolongation QT Imaging QUC398 QULIPTA QURE Qilu Pharmaceutical Qlaris Bio Qlex QuEEN Qualification QuanBio QuantHealth Quantitative (qualifier value) Quantitative Continuous Scoring Quantori Quest Analytics Quest Diagnostics Quotient Therapeutics Qureight Quviviq R&D chief R&D setbacks R&D shutdown R&D strategy R0 completely resected RAS cancer RAS-addicted cancers RAS-mutated RAS/RAF inhibitor RBM39 gene RCQ RCT RDX-002 RE104 REACH-DMD study REACtiVe-2 REDEFINE-4 weight loss REGENERATE-PD REM-422 RENOIR RESTORE-FA RET Inhibitor RET protein, human REVEAL-1 REZOLVE-AA REZOLVE-AD RFK Jr. rhetoric RFK Kennedy RGI-C scores RIDDL RIFs RIGL RIPK1 protein, human RIPK2 RIPK2 scaffolding inhibitor RMTX RNA Splicing RNA Vaccine RNA delivery RNA drug RNA exon editing RNA gene RNA medicine RNA medicines RNA obesity RNA technology RNA test RNA therapies RNA-LNP RNA-targeted medicine RNA-targeting RNAi medicine ROR1 protein ROR1 protein, human ROS1-positive Lung Cancer ROS1-positive NSCLC ROSA Knee ROSELLA trial RP1 melanoma RPE cells RPTR-1 RQ Bio RQB01 RRP RS- RSNA RSV antibodies RSV vaccine RTU cartridges RV-8451 RVO RVU120 RVUs RWE RXRX RZLT Race:Type:Point in time:^Patient:Nominal Rachael Racism Radar Therapeutics Radiance Biopharma Radicava Radiology Specialty Radiometry Radionuclide therapy Radspherin Rahway Raised Rakuten Medical Rallybio Rallybio RLYB212 Ramp Rancho BioSciences Randomized Controlled Trials as Topic RaniPill Ranluspec Ranluspec Lucentis Ranluspec ranibizumab-hkdz Ranluspec vials Rapid Edge Cloud RapidAI Ratio Therapeutics Ravi Thadhani RayThera Readiness Reading (activity) ReadyFlow Autoinjector Rebate Model Rebeca Villarreal-Barragan Receptors, Islet Amyloid Polypeptide Reciprocal Reclassification Recludix Pharma Recognify Life Sciences Recurrence Risk Reduced Reflex Refractory Plasma Cell Myeloma Regeneron Pharmaceuticals Regeneron Warren Regulation of biological process Regulatory Authority Regulatory Crackdown Regulatory Expertise Regulatory Framework Regulatory Impact Regulatory Path Regulatory Pathway Regulatory T-Lymphocytes Reindeer Reinvent Reinvention Relapsed/Refractory Relative (related person) Relay Device Relay Therapeutics Relieving Religious Missions Relmada Relyvrio RemeGen partnership Remepy Remix Therapeutics Remote Internship Remote control command - Clear Renal function Renalys Rentosertib Rentschler Rentschler Biopharma Repare Reperio Health Research Infrastructure Research Organization Research Projects, R-Series Research Triangle Park Reshma Kewalramani Resistance (Psychotherapeutic) Resistant hypertensive disorder Resolve platform Resources Respiratory Distress Syndrome, Adult Respiratory rate Response Evaluation Criteria in Solid Tumors Restricted Resume - Remote control command Resumption Retifanlimab Retinoschisis Retreatments Retro Biosciences Retrotransposons Return on Investment Return to (contextual qualifier) (qualifier value) Reunion Island RevMed Revenue Milestone Reverba Global Reverse Stock Split Review Voucher Revita Reviva Pharmaceuticals Revolution Vibe CT Revolution daraxonrasib Revuforj Rezatapopt Rezolute Rezon Bio Rezurock Rezzayo Rhode Island Rhythm Ribo Ribupatide Richard Richard Fair Richard Gonzalez Richmond Rick Fair Rick Osterloh Rickets Ridgefield New Jersey Riliprubart Ring Sideroblast Status Rinvoq growth Risdiplam Rise Up trial Risk Reduction Rivus Pharmaceuticals Rob Michael compensation Rob Pinataro Robert Kramer Robert Malone Robert Michael Robert Warner Roche 's Roche Diagnostics North America Roche Tecentriq Rocket Pharma Rocket Pharmaceuticals Rocklin Lab Roctavian Roger Perlmutter Roivant Sciences Rolvedon Ron Renaud Ronald A. Williams Ronde-cel Roopal Ross Haghighat Rotation Round three Royalty Pharma Royalty-Driven Model Rubella Russia Russian language Rx refill Ryan Richardson Ryvu Rznomics SABCS25 SAFEbody technology SALT score * * SANDCAT trial SARC041 SARM1 Inhibitors SASAC SASS SASTIND SAT-3247 SAVITRI SB-01 SB36 SBA SBX sequencing SC0062 SC451 SCAN disorder SCLC SCN10A gene SCN1A gene SCN2A mutations SCOPE IO SCOPE trial SCOTUS SEC SEED Therapeutics SENS-501 SEP-786 SERENA-6 SERON SERP-01 SERPINA1 gene SGR-2921 SGT-003 SHORE SHP-DB1 SHTG SIK2 gene SIM0505 SIM0709 SITC SKB105 SKIA SLC17A5 gene SLTE-1009 SLV-154 SLV-324 SMA SOHO SOL-1 SOLAIRIA-1 SOLAIRIA-2 SPAG8 gene SPG302 SPRB SPaL SRP-1003 SRP-9003 SRSD107 SSGJ-707 ST-01156 STARLYS trial STAT6 STAT6 protein STELLAR-303 trial STI-based STOMP2 STOP-V1 STOP-V2 ) STP-100 STX-001 STXBP1 gene SUCCESSOR-2 SUNMO SUNY AI Symposium SURMOUNT-5 Trial SURMOUNT-MAINTAIN SURPASS-CVOT SURPASS-PEDS SURVEY.ALSFRSR SW-682 SYD-101 SYK SYNC-T Sabeen Mekan Sackler family SafeBeing platform Safety Data Safety Issues Safety labeling Sagimet Sahil V. Kirpekar Sail Biomedicines Sailaja Battula Sales growth Sam Roosz Samit Samsara Samsung Bio Samsung Bioepis San Rafael Sana Biotechnology Sanacor Sangamo Therapeutics Sanjay Sanjula Jain-Nagpal Sanofi Blueprint Medicines Sanofi Strategic Sanofi acquisition Santen Santé Ventures Sapablursen Sapio Sapio Sciences Sapu Nano Sapu003 Sapu006 Sarah Boyce Sarbani Sarclisa Sarcoidosis, Pulmonary Sarcoma, Epithelioid Sasanlimab Sasineprocel Satellos Scaling Laws Scancell Scheme of Arrangement Schott Schweizerhalle SciSparc Science of Microbiology Science of genetics Scientific Context Scientific Data Scientific Sessions ScinoPharm Sciwind Sciwind Biosciences Scorpions Scott Howell Screens (device) Scripps Research Seagen acquisition Seattle Office Closure Section 232 Section 301 Section viii Sector Security Measures See-Mode Self-Injectable Self-Management Self-injection Self-pay Semcap AI Semerjian Senators Senile cardiac amyloidosis Senior - Suffix Seno Medical Sensei Biotherapeutics Sensorineural Hearing Loss (disorder) Sensorion Sensorion hearing loss program Sentire Surgical System Sentynl Senzime September 23 Sequestration Seralutinib Serbs Seres Sergio Marullo di Condojanni Series B fundraising Series C financing Series C funding Series D equity Series D1 Series E Series E funding Series F Series F financing Serif Biomedicines Serine/Threonine Kinases Serious Seronegative Serplulimab Sevaro Health Severities ShORe Shadow Shandong healthcare Shane Speirs Shankar Ramaswamy Shapes Shareholder Ownership Structure Shareholders Meeting SheMed Sherwin Sattarzadeh Shield Shigella Infections Shigella Vaccines Shin Ashida Shingrix competitor Ships Shock Shooting sensation quality Shortened Sialic Acid Binding Immunoglobulin-like Lectins Sibel Health Sickle Cell Siemens Healthineers Signal Signal Transduction Signatera Simplexvirus Simufilam Single Agent Therapy Single-Domain Antibodies Siran Biotechnology SiranBio Sirexatamab Sirius Sirona Medical Sironax Sitala Site Closure Site of exit Sjögren 's disease SkinJect SkyEngine Slate Medicines Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep disturbances Sleep medicine specialist Sleeplessness Smart Health Map Smart contact lenses Smoldering myeloma Social Media Society for Neuro-Oncology Software as a Medical Device Solid Biosciences Solubility Solutions Solve Therapeutics Solventum SomaLogic Somatix Sonia Sotatercept Sotyktu BIOPHARMA South Korean biotech Southern Sotho language Spago Nanomedical Spain Sparrow Pharmaceuticals Spatial Mosaic Specialty pharma Specimen Spectral AI Spectrum Profiling Spero Therapeutics Spevigo Spine BioPharma Spinogenix Spiriva Respimat Spondylarthritis Spravato Spring Health Spruce Biosciences SpyGlass Pharma ( SpyLock technology SpyTag/SpyCatcher Squamous cell carcinoma Squamous cell carcinoma of skin Squamous cell carcinoma of the head and neck Squibb Layoffs Squibb partnership Srikanth Pendyala Stabilization Stable angina Stable status Staphylococcus aureus StarTrack3 State Room Statement Status Quo Steam Stein facility Stelara Decline Stemchymal Step Pharma Stephen Hemsley Stephen Hoge Stephen P. Dale Steve La Neve Steve St. Onge Steve Tomlin Steve Ubl Stevenage facility closure Stimulation procedure Stipple Bio Stock Reaction Stoke Storm Therapeutics' Strategic Brands Strategic Deals Strategic Growth Strategy Stratify Dx Stratus Strensiq Stress Stress Fractures Strive Pharmacy Structure Structure of hippocampal commissure Structure partnership Stryker Stuart Pharmaceuticals Stéphane Bancel Subacute Care Subcutaneous Cancer Sublocade Subsidies Substance Abuse Detection Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance) Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) Success Summer SunRISe-1 trial Suneet Varma Sunita Mishra Super Bowl 2025 Super Bowl ads Superficial ulcer Superluminal Medicines Supernus Supervisory Board Supply chain disruption Support Services Program Supportive care Supranuclear paralysis Supreme Court stay Surgeon Surgical Replantation Surgical Robot Surrogate Surveillance: safety Susan Susvimo Sutro Suvretta Capital Management Suzanne Winter Swift Medical Swift Ray SwiftFluo Swissmedic Swixx Group Swoop Sydnexis Sylvia Isler Symptomatic SynAIRgy SynKIR-110 SynKIR-310 Synapse AI Synbio International Inc. Syncromune Syndax Syndeio Syngene Synnovation Synthesis Syphilis, Congenital SystImmune System T business T cell therapy T cell-targeted T-Bolt T-Charge T-DXd T-cell malignancies T-cell therapy TA-ERT TACTI-004 TAF8 wt Allele TAILORED-AF TAK-861 TAK-921 TAS-205 TB Alliance TB-500 TCEs TCR TCR-NK cell therapy TEAEs TECVAYLI TECregen TESARO TETON-2 THB335 THETA platform THRIVE-2 TIDAL-01 TIGIT antibody TIL cell therapy TJ Biopharma TKI TLN-121 TLN-254 TLN-372 TLR7/8 TLX2 gene TMP-301 TNF gene TNGX TOGETHER-PsO TPRG1L gene TR-FRET TRANSCEND TRANSCEND-T2D-1 TRBV9 gene TRCN-1023 TREX1 gene TRICORDER TRIDENT trial TRIM21 TRIMTAC TRIUMPH TRIUMPH program TRIUMPH-1 TRLN TRONTIER TRPC6 inhibitor TRPV4 protein, human TRVI TRiM platform TSHA-102 TSX TScan Therapeutics TTAM TULIP-SC trial TV ad TYK2 TYK2 Inhibitor TYR wt Allele Tace TaiGen Biotechnology Takeda FDA filing Takeo Takhzyro Taltz Talzenna upstream data ASCO Tampa Florida Tanabe Pharma Tang Tanruprubart Tarlatamab Tassos Gianakakos Taxes Taysha Gene Therapies Tecan Tech Rivalry TechLive Technology, Health Care Ted Love Tedopi Teijin Teladoc Television Tempero Bio Tempus Tenvie Tepezza Tepkinly Termination - Inactive Reason Code TerraBind Terremoto Terry Fox Research Institute Test Result Testiculo- TetraGraph Texas Facility Texas Tech Thad Huston Thakkar Therapeutic Antibody Therapeutic Index Therapeutic Mobilization Therapeutic radiology procedure Thetis Study Thick Third Circuit Court Third Harmonic Bio liquidation Third line treatment Thomas Hartung Thomson Reuters Thousand Oaks Thrive Thrive Capital Thrombotic Stroke Thyme Care Thyroid Diseases Tidmarsh Tim Van Hauwermeiren Time Timothy Wentworth Tinnitus Tiragolumab Titania Titles Tiziana Life Sciences Tokyo Stock Exchange Tomi Sawyer Tonix Tonmya Topco Tortugas Toru Ashida Total Improvement Score Tourette 's syndrome Tourmaline Bio Toxic Epidermal Necrolysis Toxic Oligomers Toxicology Tozorakimab Trace Neuroscience TraceNET Tracer Tracy Beth Heg Traditional Medicine Trail Making Test Transcarent Transcranial magnetic stimulation Transdermal Route of Drug Administration Transfection Transfer RNA Transformation Officer Transformational Data Transforming RNA Medicine Development Translational Oncology Transplantation Transposition of Great Vessels Trastuzumab Rezetecan Travel Health Travere Treatment Adherence Treatment Effectiveness Treeline Biosciences Tregs Trevi Therapeutics TriNetX Trial Phase Trial Termination TrialBlazer Trinity (ethnic group) TruTCR TrueLab Biopharmaceutical Trump 's Trump administration reforms Trump administration tariffs Trump budget Trump executive order Trump import tariffs Trump policies Trump tariff Trust (Social Behavior) Truvada Truveta report Tukysa Tumor Microenvironment Tumor Suppression Tumor board Tumor stage Tis Tumor-Infiltrating Tumorad-01 Tumorigenicity Tumour treating fields therapy Turbine Turitz Tyler Sloat Type A meeting Type II JAK inhibitor Tysabri Tyvaso Tzield U-turn U.S. Food and Drug Administration UCCD UK 's UK-US UNC13A gene UNLOXCYT UPB UPCR US-China competition US-EU USPTO UTP-monosaccharide-1-phosphate uridylyltransferase activity UgeneX Ugur Sahin Ultomiris Ultreon 3.0 Undetectable Unicorn births Uninsured United Imaging Healthcare United Laboratories International Holdings Limited United States Agency for International Development Universal Universal Cells University of California Unixell Biotech Unravel Unspecified Abortion UpToDate Expert AI Updates Upstream Bio Uptake Urcosimod Urinary Bladder Urinary hesitation Urine culture Urology Urticaria Urticaria due to cold Usher Syndrome Type 1B Usona Institute Utebzi Uwe Buecheler VAL-413 VALOR VALOR study VAV1 protein VAX-24 VAX-31 VAY736 VAYHIT2 trial VBDS VCT220 VDPHL-01 VELO VENT-02 VENT-03 VESALIUS-CV trial VESPER-2 VHH VHH Immunoglobulin Fragments VISIONARY VISTA trial VISTAS study VITALIZE VIZZ VLA15 VMAT2 Inhibitor VMX-C001 VRDN-003 VWF wt Allele VX-993 VY1706 VY7523 VY9323 VYJUVEK Vaccination Hesitancy Vaccine Company Vaccine Efficacy Vaccine Reform Vaccine Testing Vaginal Microbiome Valar Labs Valiltramiprosate Valinor Vamikibart Vanda Vanderbilt University Medical Center Vanrafia VantAI Variant Bio Variation (Genetics) VarmX Vascular anomaly Vaseline Vasudev Bailey Vault Vaxcyte VectorY Vedana Therapeutics Veeva Systems Vega Therapeutics Veklury VelaVigo Vemircopan Ventana Medical Systems * * Venture Exchange Verastem Veraxa Verge Labs Verification Verily Verily Me Verismo Therapeutics Versant Vertex Veru Vesta <beetles> Vestibulo-Ocular Vevzuo ViVac Pharma Viatris Vibrance-1 study Vicebio Vidofludimus Calcium View View Bora ViewPoint EchoPilot Viewer Device Vigil Neuroscience Viking Global Investors Villya Pharmaceuticals Vimseltinib Vinay Prasad FDA memo Vincentage Vincentage Pharma Vineet Agrawal Violence Violet AI Viome Viral Viralgen Virginia Virginia facility Virginia plant Virtual Cell Model Virtual Geneticist Virus-Like Particle Visible Vision Restoration Vistagen Visual Suppression Visugromab Vital capacity test Vitiligo Vitor Roque Vivtex Voluntary Scheme Vomiting Vor Bio Voucher Voxzogo hip injuries Voyager Therapeutics Vunakizumab Vyglxia Vyondys 53 Vyvanse Vyvgart Hytrulo WARN WARN filing WARN notice WEE1 WEE1 inhibitor WHIM syndrome WP1066 WRN inhibitor WVE-N531 Wakefulness Test Walgreens Boots Alliance Walmart partnership War-Lock platform Warning Letter Warsaw-Duchnice Washington pushback BioSecure Act COINS Act 2025 John Moolenaar Myers Squibb Hengrui Pharma Wuxi AppTec Washington state Waukegan WeDosify Wearable Behavior Model Wearable Electronic Devices Wearable biosensors Web Site Wehr Weight Watchers Weldon Weldon 's Welfare Werner Syndrome Werner helicase Westborough Massachusetts Western biotech Western patients Wet AMD Wet Age-Related Macular Degeneration White House liaison Whooping respiration William Blair Wilmington Windward Bio Withdrawal Symptoms Wolfgang Wienand Wolters Kluwer Health survey Women Workforce Working Group World WorldMeds Wounds - qualifier Written - Consent Mode WuXi Biologics' Wuhu X-Cell X-Linked X-linked retinitis pigmentosa XHANCE XOMA XOMA Royalty XPro XR Xaira Therapeutics Xanthomatosis Xarelto Xarelto patent Xencor Xenograft procedure Xenon Pharmaceuticals ' Xevinapant Xianweiying Xilio Xolair Xolremdi Xpovio Xpress Wellness Xspray Pharma XtalPi Y-mAbs Y220C mutation YB-101 Yarrow Bioscience Yervoy Yidafan YolBE YolCas Yosemite Young Adult Young Talent Yvonne Greenstreet Z-1018 ZENEO® ZENITH trial ZEPIZURE ZG006 ZI-MA4 ZIMA-101 ZM-02 ZUSDURI ZW171 Zaka Zami Aberman Zanidatamab Zealand Zegfrovy Zelgen Zelis Zelluna Zemaira ZenGUARD Zenkuda Zentalis Zentek Zepbound KwikPen Zephyr AI Zervimesine Zhongmou Zifo Zilebesiran Zilovertamab Zinc Fingers Zokinvy Zongertinib Zonsen PepLib Zoë Zuellig Pharma ZyDoc aDBS aGvHD aTyr abdakibart abelacimab abemaciclib acasunlimab accelerating development accelerator acceptance access strategy accessible aceclidine acquisition talks acquisition termination active pharmaceutical ingredients activin signaling acute graft acute systemic infection acute treatment adaptive deep brain stimulation adaptive dosing adeczibart adjunctive therapy adjunctive treatment adjuvant Tecentriq adjuvant setting adjuvant treatment admilparant administrative law administrative proceedings advanced breast cancer advanced manufacturing advanced solid malignancies advanced solid tumors advanced sqNSCLC advanced therapeutics advisers advisory advisory appointments advisory meetings advisory panels aesthetic treatments affairs aflibercept age restriction age-related diseases agency departures agency instability agency staffing shortages aggregator agile agilon aging reprogramming aging-related diseases aglatimagene agreement rate aleniglipron all-cash tender alliance allogeneic cell therapy allogeneic hematopoietic stem cell transplant with purging alpha opportunities alpha radioligand therapies alpha radiopharmaceutical alpha-synuclein antibody alternative testing alternatives aluminum potassium sulfate ambulatory care services ametefgene parvec amezalpat amivantamab amsacrine/azacitidine/etoposide amyloid beta antibody amyloid-beta amyloid-lowering drug analytics anaphylaxis anifrolumab anitocabtagene autoleucel annamycin annualized height velocity anti-APRIL antibody anti-CD47 monoclonal antibody anti-EGFR anti-PD-1 anti-VEGF therapy anti-aging anti-amyloid antibody anti-amyloid drugs anti-fibrotic anti-vaccine movement antibody candidates antibody collaboration antibody design antibody humanization antibody reactome antibody therapeutics antibody-chopping drug antibody-targeted antisemitism antisense antithrombin III antitrust litigation antitrust review antitrust verdict anvumetostat apalutamide apatinib apecotrep apical plasma membrane urothelial plaque apomorphine hydrochloride applicability application assessment appropriations approval status approval sweetener arcotatug argenx Vyvgart aroxybutynin artemether-lumefantrine artificial dyes artificial luciferases aseptic manufacturing asset acquisition asset termination assumes assurance at-home at-home colon cancer at-home screening at-home treatment ataluren atlases atogepant atomoxetine attraction attractiveness auction autoimmune drugs autoinjectors autologous cell therapy autologous neurons autonomous avibactam avutometinib plus axon degeneration axonal degeneration azetukalner aztreonam b.well partnership backer bacterial detection baldness cure bankruptcy filing becton dickinson belumosudil bemarituzumab benefit-risk profile benralizumab berobenatide bespoke bevacizumab bexmarilimab bidders bile acid therapy biliary cholangitis bimagrumab bimatoprost IOL bimekizumab biochemical recurrence bioequivalence bioequivalence testing biofilm-driven chronic respiratory disease biologic blockbusters biomanufacturing jobs biomarker qualification biomarker test biomedical foundation models biomedical innovation biomolecular AI biomolecular structure prediction biopharma agents biopharma exit strategy biopharma financing biopharma fund biopharma industry biopharma job biopharma regulation biopharma startups biopharma survey biopharmaceutical company biopharmaceutical innovation biopharmaceutical partnership biopharmaceutical sector biopharmaceutical startups bioprocess biosimilar competition biosimilar guidance biosimilar medicines biosimilarity biosimilars approval biotech careers biotech closure biotech collaborations biotech crackdown biotech dealmaking biotech employment biotech executive biotech finance biotech financing biotech incubator biotech leadership biotech licensing biotech pivot biotech spinoff biotech strategy biotech workforce biotechnology innovation biotechnology layoffs biotechnology partnerships biotechnology services bipartisan criticism bird flu vaccine birtamimab birth dose bispecific bispecific antibody screening bispecific antibody technology bispecific competition black-box warning bleomycin/dacarbazine/lomustine/vincristine blockbuster drug blockbuster sales blocker blood clotting drug blood pressure ambulatory blood pressure pill blood sugar control blood vessel disorders blood-based cancer board members board restructuring board shake-up body proportionality bone lesion prevention bonus boost booth bortezomib brain fluid brain organoids brain shuttles brain volume brain-penetrant brain-penetrant delivery brand-name brand-name drugs brand-name prescriptions branded medicines brengitecan briquilimab broaden business options business plan business practices business split business strategy business unit butyrophilin superfamily buying spree cAMPfield cDNA display proteolysis cGAS inhibitor cGVHD cUHDRS cUTI cUTIs cabotegravir calcific aortic valve stenosis calcium campaign campaigns canakinumab cancellations cancer antigen therapy cancer biotech cancer diagnostics cancer drug sales cancer funding cancer intelligence cancer medicines cancer prediction cancer proteins cancer research trends cancer testing cancer therapeutics cancer treatments cancer trials capacity quadruple capital constraints capital investment capivasertib capivasertib PIK3CA AKT pathway capsid delivery cardiac research cardiac safety cardiac safety signal cardiac sarcomere modulator cardiometabolic care cardiorenal medicine cardiotoxicity screening cardiovascular asset cardiovascular benefits cardiovascular gene therapy cardiovascular program cardiovascular safety cardiovascular screening cardiovascular trial career cargo receptor ligand activity cartilage degradation carve-out casdatifan cash balance cash dividend cash-paying cell analysis cell classification cell therapy sale cell therapy sales cell transfer cell transformation cell-associated neurotoxicity cell-cell project cell-device combo cell/gene therapy cellular rejuvenation cema-cel cemdisiran centanafadine central reads central subfield cerebrotendinous xanthomatosis cetuximab chairman resignation charmed checkpoint inhibitor-resistant chemical alternatives chemical modifications chemical space chemo-displacement chemo-turned-gel drug chemotherapy-free regimen chenodeoxycholic acid childhood health chinese medicine cholesterol ester transfer protein inhibitor cholesterol-lowering choline chronic disease epidemic chronic disease management chronic graft-versus-host disease chronic health conditions chronic hepatitis delta virus chronic hives chronic thyroid eye disease cisplatin-eligible cisplatin-ineligible citizen petition cityRNA civil civorebrutinib class action clawback rate clazakizumab clean sweep cleavage-inducing tiny RNAs clemidsogene lanparvovec cleminorexton click clinic entry clinical dataset clinical diagnostics clinical holds clinical improvement clinical operations clinical outcomes clinical queries clinical reproducibility clinical research services clinical results clinical seizure clinical terminology clinical trial conduct clinical trial halt clinical trial pathway clinical trial results clinical trial review clinical trial update clinical update clinical visualization clinical worsening clinical-stage clinical-stage AI startups clinical-stage biopharma clinical-stage biopharmaceutical clinical-stage biotech clinical-stage biotechnology company clinical-stage companies clinical-stage company clinical-stage immunotherapy clinical-stage pharmaceutical clinicogenomics clofutriben clone stability closed-loop interventions closed-loop systems co-development co-exclusive license co-location coalition cognition cognitive improvement cognitive side effects collaborative framework collaborative healthcare coloplast commercial supply chain commitment community grants community-oriented clinical trials companion diagnostics company closure company transformation compensation pharma competition rules competitive weight loss medication complement system complete response rate complete responses compounding pharmacy computational drug discovery computational pathology computational protein design computational protocol concept concerns safety concessions conditional approval pathway conditioning regimens confident confidentiality confirmatory study confirmatory study failure conflict of conservative criticism conspiracy constitutional challenge constitutionality consumables consumer relationship content intelligence contextual errors contingent value contingent value rights continuous continuous trial contract cancellation contract extension contract manufacturer contract research control act - information controllable controversy conversation conversion factor convertible cooperation copper histidinate copper isotopes cornea surgeon corneal endothelial disease coronary imaging coronary trial corporate development corporate governance cortisol modulator cost reduction cost-cutting initiatives cost-effectiveness cost-reduction cost-saving country-of-origin labeling covalent binding drugs covalent biologics covalent chemistry covalent drug discovery cranial neurosurgery crash craving control credit card fees critical bleeding crizanlizumab crofelemer cross-border cross-border pharma ctDNA ctDNA-guided therapy customer-facing organization customs loophole cut corners cutaneous remission cyclic adenosine-5'-trimetaphosphate cyclobenzaprine cynicism cytisine cytotoxic T-lymphocyte antigen 4 daily pills daisy danegaptide daratumumab daridorexant darlifarnib data bottlenecks data breach data gaps data generation data harmonization data misinterpretation data modernization data secrecy data solutions data stewardship data stolen data-driven decisions data-driven health data-driven innovation de novo miniproteins deal activity deal termination death risk reduction debt maturity extension debt obligations debut deceptive marketing decision day decision science defactinib deficiencies degrader antibody conjugate delgocitinib delist delivery options demerger demyelination dencatistat depression drug deprioritization deruxtecan-nxki developmental restoration device regulation diagnostic kit diagnostics industry digital coaching digital dermatology digital enablement digital endpoints digital health records digital health regulation digital health screener digital infrastructure digital marketing digital medicine digital microfluidics digital pathology prognostic test digital quality systems digital solutions digital therapeutic digital tools digital twin diluted cardiomyopathy dimethylethylsilylimidazole direct-to-consumer ( DTC ) direct-to-employer direct-to-patient model director director firing directors disability services discounts discovery engine disease activity disease awareness disease clinical trials disease control rate disease drug disease program disease research disease therapies disease treatment disease vouchers disease-modifying treatment disorder control (procedure) disparagement dissolvable distributor network divestiture divestitures domestic pharmaceutical industry domestic production domestic supply chain doravirine doravirine/islatravir dotinurad doubt downsides downsizing downturn draft report drug activity drug ads drug affordability drug application drug approval outlook drug candidates drug combo drug competition drug conjugates drug delivery innovation drug delivery platform drug development pipeline drug development sentiment drug discontinuation drug discount program drug failure drug import duties drug import plan drug importation drug imports drug ingredients drug lag drug licensing drug manufacturers drug markups drug optimization drug pipeline drug price discounts drug price negotiation drug prices fall abroad drug pricing plan drug pricing policy drug production drug quality drug rebates drug rejections drug relabeling drug reviews drug sales drug-resistant drug-resistant TB drug-resistant focal seizures drug-to-data pivot dual pathway inhibition dual-agonist dual-payload ADC dual-payload technology dual-targeting dulaglutide duplicate discounts durvalumab dwarfism trial e-posters eGenesis eRNA earlier-line treatment early disease early-phase trials early-stage trial earnings beat ecnoglutide efdoralprin alfa efimosfermin alfa efzofitimod elacestrant elebsiran electronic health record - ActClassContainer elenestinib elinzanetant eloralintide elranatamab emergency medicine (field) emiltatug ledadotin emotional dependency employee layoffs employment employment reduction emugrobart enLIGHTEN Discovery Platform enforcement action enforcement letters enfortumab enfortumab vedotin engine engineered peptides enlicitide decanoate enobosarm enrollment forms enrolment ensitrelvir entera enterprise reorganization entry - ActRelationshipCheckpoint environmental enzyme engineering enzyme restoration enzyme technology eosinophil epigenetic editing epigenetic modulator epigenetic therapy epinephrine equity buyback equity financing equity upside ersodetug esreboxetine estate estrogens etanercept etrolizumab evaluation event cycle everolimus evidence-based evolocumab exagamglogene autotemcel exclusivity extension executive actions executive changes executive exits executive survey executive team executive vice president existential threats expanded label expansions expedited pathway expertise experts booted expirations exploitation external control group external controls external partnerships extrahepatic RNAi eye treatment facilities facility closure facility consolidation factor XIIa factory closure fam-trastuzumab fantasy-romance farabursen farm-to-hospital faster fat loss fat reduction federal AI federal agencies federal courts federal directives federal grants federal workers fee structure fenebrutinib fentanyl fibroblast immunology fibrodysplasia fibrosing fidrisertib field ablation figures filing checklist final analysis financial guidance suspension financial outlook financial recovery financial strategy financial struggles financial troubles financing strategy finerenone firi-cel firing first-in-class antibiotic first-in-human trials first-line maintenance fiscal five-year flagship office flaws flu/COVID-19 foreclosure proceedings foreign direct investment foreign factories formula update formulary exclusion formulations four-letter suffix framework franchise frataxin frataxin protein fratricide-resistant free trial frontline AML full-year guidance fumaric acid function funding agreement funding bill funding cut funding environment funding lapse funding rounds fungal prophylaxis gallium gamgertamig gamma secretase inhibitor gamma-linolenic acid garadacimab-gxii gastric inhibitory polypeptide receptor gastroenteropancreatic neuroendocrine tumors gastrointestinal gemcitabine intravesical system gemcitabine releasing system gene delivery process gene modulation gene therapy platforms gene variants gene writing gene-editing therapy general-purpose generative design generative models generic competition generic manufacturing generic medications generic semaglutide generic tirzepatide genetic cell genetic data genetic diagnosis genetic dilated cardiomyopathy genital lesion reduction genome engineering genome screening genomic analysis genomic drug discovery genomic medicines genomics AI genotoxicity geopolitical factors geopolitical risk gildeuretinol glatiramer acetate global commercialization global competition global competitiveness global drug development global drug pipeline global growth strategy global headquarters global health programs global health security global license agreement global network global price global research collaboration global sales global strategic R&D center global strategic collaboration global strategic partnership global strategy global trade tensions global trial global workforce reduction glycoengineering glycosylation go-to-market models golden decade golimumab government events government programs government review governmental engagement grace granite grant cancellation green energy green list green manufacturing gross profit growth Z-score growth drivers growth opportunities guidance raise guidance upgrade guidances gusacitinib hair loss treatment halt hand sensation harassment head-to-head psoriasis head-to-head trial headcount health coverage health data privacy health industry health officials health prediction health records health system partnerships health systems health tracking health workers healthcare AI healthcare IT healthcare agencies healthcare analytics healthcare appointments healthcare benchmark healthcare budget healthcare changes healthcare executive healthcare finance healthcare financial performance healthcare funding healthcare infrastructure healthcare legislation healthcare marketing trends healthcare operational healthcare operations healthcare payments healthcare specialist healthcare trends healthcare workflow healthy lifespan healthy longevity heart drug heart risk-benefit debate guidelines height velocity hematologic cancers hematologic care hematoxylin and eosin ( H&E ) stained hemoglobin response hemophilia A program hepatitis B functional cure hepatitis B policy change heroin herpesvirus 2, human heterozygous high-dose high-dose regimen high-performance computing high-risk patients high-throughput higher risk higher-value reagents highest-paid pharmaceutical CEOs hindrance hiring challenges hold-and-kill homegrown hormone receptor-positive hospital apps hospital intervention hospital nutrition host disease human-relevant models huntingtin-lowering hyaluronidase hydroxyurea hyper-personalized engagement hyperscaled data iMTP iNHL iPSC-derived iPSCs iSCIB1 + idiopathic Parkinson 's disease illegal immigration iloperidone iluzanebart image management imaging AI immune compromise immune disorder therapy immune mapping immune profiling immune protection immune signaling pathways immune system reprogramming immune-mediated diseases immune-related adverse events immuno-dermatology immuno-fibrosis immunoglobulin G immunology drug development immunotherapy drugs implantable device implementing import rules import taxes impurity in situ in vivo studies in vivo therapy incidents inclacumab incretin secretagogue incretin therapy indictment individual choice individual-based decision-making induction trials infant infestation influenza prevention inhaled drugs inhaled lung disease inhaled therapies inidascamine initiation protocol injectable obesity therapy innovate innovation centre innovation grants innovative drugs innovative medicines innovative trial inorganic pyrophosphate insider insider trading insolvency insulin delivery insulin icodec-abae insulin production integrated decision-making integrated solutions interferon pathway interim interleukin-11 interleukin-12 interleukin-23 receptor activity interleukin-3 interleukin-4 intermediate-risk internal disagreement internal rate internal tensions international drug international operations international pricing international trade internet phrase internship intestinal growth intisemeran intra-abdominal infections intraoperative guidance intrathecal delivery intrathecal formulation intravenous delivery intravenous formula investing investment cutback investment grants investor rescue investor sentiment irAE isolator technology itolizumab ixekizumab ixovec iza-bren izalontamab judgment jumping gene jumping genes juniper tar jurisdiction kickback scheme kidney drug kidney therapeutics kilobase pairs kinase inhibitor [EPC] kininogenase kyron.bio lab results lab space label extension label update labeling change labeling changes laboratory modernization laboratory reform programme lack of lack of transparency lanifibranor large-scale manufacture laru-zova late recurrence risk late-stage assets late-stage clinical development late-stage testing layoff leaders leadership shake-up lean muscle lecanemab-irmb legal victory legality lenacapavir weekly lender takeover lentiviral vector lentiviral vectors lenvatinib letrozole leuprolide levacetylleucine levodopa license suspension licensing restrictions lidERA life science incubator life sciences companies life sciences fund life-extension life-saving medicine likeability lincomycin linezolid liquidation live event liver enzyme elevation liver mRNA medicine loan financing localization locally advanced locally advanced head locally advanced risk long-acting injectable long-acting injectables long-acting protection long-acting therapies long-acting therapy longevity science lorlatinib loss of function loss treatment lotiglipron low low-cost lower dose lower-risk myelodysplastic syndromes lunbotinib fumarate lung scarring lunsekimig lupus skin drug lurbinectedin lymph nodes lymphocyte immune globulin, anti-thymocyte globulin lymphocyte-activation gene 3 protein lymphocyte-activation gene 3 protein, human mAbxience mCSPC mCombriax mFARS mGnP mNEXSPIKE mRESVIA mRNA contracts mRNA degrader mRNA misinformation mRNA production mRNA therapy mRNA-1083 mRNA-1283 mRNA-1647 cytomegalovirus vaccine mRNA-4359 mRNA-based mRNA-based Personalized Cancer Vaccine mRNA-4157 mRNAs mTNBC machine learning model macroeconomic macrophage-based programmes macular maintenance phase malignancy risk malignant haematology management layers management technique mandates manufacturing campus manufacturing challenges manufacturing closure manufacturing consolidation manufacturing deficiencies manufacturing license manufacturing organization manufacturing practice manufacturing process manufacturing shutdown manufacturing uncertainty marketing authorisation marketing officer marketplace marstacimab mast cell therapy match Eylea maternal-fetal monitoring mazdutide measles, mumps, rubella, varicella vaccine measurable outcomes mechanistic trials mechanoporation med-tech median employee medical advancements medical benchmarks medical breakthroughs medical data medical device company medical documentation AI medical freedom medical groups medical jargon medical leadership medical review medical supplies medical supply chain medical technology exemptions medical wearables medtech industry meeting cancellation mega depots megascale melanin-concentrating hormone melanoma drug membranoproliferative glomerulonephritis men 's health menen inhibitor mental health innovation merger cancellation mesothelin metabolic dysfunction-associated steatohepatitis metabolic health metabolic medicines metagenomic sequencing metastatic solid tumors metastatic triple-negative breast cancer methylone mezigdomide mezigitamab mice studies microdosing microenvironment microneedle patches microneedles microparticle technology microservices mid-2030s mid-stage middle dose middle-income countries middlemen midline glioma midterm milestone payment milsaperidone mini-proteins minimis exemption minimization miniprotein design suite missed milestone mitazalimab mivelsiran molecular AI molecular entities molecular glue degrader molecular modalities molecular point-of-care molecular residual disease moments monogenic kidney diseases month most-favored most-favored-nation pricing motor fluctuations motor milestones mouse models movers mucosal healing multi-agent system multi-agent systems multi-cancer early detection multi-cancer screening multi-cancer tests multi-domain proteins multi-institutional research multi-medicine platforms multi-omic strategies multi-payload multi-program collaboration multi-sensor multi-specific antibodies multi-target collaboration multi-year collaboration multibillion-dollar market multiforme multimodal approach multimodal data multiple disease areas multiplex test multispecific antibody muscle disease therapy muscle health muscle loss muscle strength endpoint muscle-invasive musculoskeletal conditions myQA StarTrack myelin repair myosin inhibitor myostatin antibody myostatin inhibitor nAMD nHCM naloxegol naltrexone-bupropion naming convention nano-in-micro delivery nanobody nanodelivery nanoparticle delivery nanosecond naproxen-n-butyl nitrate narsoplimab natalizumab nation policy national priorities national priority review voucher national priority review vouchers national sector growth nations naturalX nature-inspired drug discovery navacaprant navenibart navtemadlin needle-free vaccines negative adcomm negative opinion negotiators nemolizumab neo-epitope cancer vaccine neosubstrate neuro injury neuro pipeline neuro-metabolic diseases neuro-rare diseases neuro-specialty diseases neurodegeneration therapy neurodegenerative neurofibroma neuroimmune disorders neuroinflammatory neurology pipeline neuropathic corneal pain neuroprotective neuropsychiatric disorders neuropsychiatric drugs neuroreparative therapeutics neuroscience division neurotechnology neurovascular AI neutrophil-mediated disease new product newco nexiguran nexiguran ziclumeran next-gen brain therapies next-gen pneumonia next-generation Covid vaccine next-generation RNAi next-generation drugs next-generation vaccine nintedanib ninth nipocalimab-aahu nirsevimab nizubaglustat nmHSPC nodularis nomination committee non-European ancestry non-FDA non-antipsychotic non-competitive profile non-cystic fibrosis bronchiectasis non-dilutive non-dilutive financing non-generic specialty non-hormonal therapy non-incretin therapies non-inferiority non-mRNA vaccine non-metastatic non-opioid non-opioid pain medication non-opioid pain relief non-opioid pain therapies non-relapsing secondary progressive non-surgical back pain noncirrhotic nonprofit webinars nonrelapsing nonresponder nonsurgical treatment options normative wakefulness nucleic acid delivery nusinersen obesity therapy obesity-related cancers obsidian ocadusertib ocular adverse events ocular delivery ocular immunology off-target offerings office closure offloading offshore older children oligomer selectivity olorofim olverembatinib omnichannel on-demand once-daily pill once-weekly once-yearly oncology acquisition oncology advancements oncology collaboration oncology combo oncology company oncology decisions oncology diagnostics oncology ecosystem oncology expert oncology licensing deal oncology market oncology pivot oncology portfolio oncology supply oncology therapeutics oncology trials oncolytic immunotherapy online program ontunisertib open innovation open science open-label extension open-source AI open-source dataset openFDA operating costs operating expenses operating profit margin operational efficiency operational transformation optimisation programme opto-acoustic imaging oral FASN oral PCSK9 oral asthma therapy oral carbapenem oral cholesterol pill oral drugs oral formulations oral inhibitors oral minoxidil oral obesity drug oral peptide oral pill vaccine oral presentation oral regimen oral small molecule RNA degrader oral small-molecule therapeutics oral small-molecule therapy oral targeted therapy oral weight loss drug orchestration orelabrtuinib orexin agonist orexin receptor type 2 organ donor organic growth orglipron orphan drug exclusion orthopedic innovation osavampator ossificans otoferlin out-licensing outbound investment overall response rate overcapacity overhangs overhaul overhype overmedicalization overseas oversubscribed oversubscribed fund ownership increase ozekibart ozureprubart p-tau217 p53 reactivator pTau217 packaging issues pain assets pain crises palivizumab pamirtecan pan-JAK inhibitor pan-KRAS pandemic influenza paradigm partial response partnering with pasritamig patent expiration patent license pathology AI patient definition patient management patient meals patient navigation patient populations patient recruitment patient-provider interaction patient-specific therapies patient-specific therapy patritumab pattern hair loss pause recommendation pay-for-delay payer paying payload payors peak sales pediatric brain cancer pediatric diseases pediatric dosage pediatric drug designation peer pelareorep penicillin recall peptide therapeutics perioperative therapy permanent role personal data personal genome service personalized cancer therapy personalized care personalized health services personalized healthcare personalized neuromodulation personalized treatment personnel change perspectives pertuzumab petition pharma TV ads pharma brand engagement pharma companies pharma consolidation pharma directors pharma division pharma industry pharma investments pharma packaging pharma patent expirations pharma policy pharma reforms pharma reshoring pharma response pharma skills shortage pharma tech pharma trade group pharmaceutical AI pharmaceutical advertising crackdown pharmaceutical backing pharmaceutical collaboration pharmaceutical commercialization pharmaceutical communications pharmaceutical delays pharmaceutical delivery pharmaceutical divestment pharmaceutical earnings pharmaceutical employment pharmaceutical imports pharmaceutical investment pharmaceutical investment Germany pharmaceutical lawsuits pharmaceutical leadership pharmaceutical licensing pharmaceutical lobby pharmaceutical market pharmaceutical mergers pharmaceutical milestones pharmaceutical rebates pharmaceutical revenue pharmaceutical setback pharmaceutical setbacks pharmaceutical trade pharmaceutical trade war pharmacy platform pharmacy reimbursement phase 2/3 trial phase 3 POIESIS trial phase 3 failure philanthropy phosphodiesterase 4B physiological aspects pilot data pimecrolimus pipeline blips pipeline cull pipeline gaps pipeline management pipeline restructuring pipeline setbacks pipeline shake-up pipeline shift pipeline update pipeline work pivekimab sunirine pivot resources pivoxil pizuglanstat placebo-adjusted improvement plant construction plasma-derived therapies plasma-derived therapy platelet levels platform immunotherapy * * pledge pneumococcal conjugate vaccines pociredir podcast political politicization poly-N-4-vinylbenzyllactonamide portfolio companies portfolio prioritization portfolio reprioritization portfolio support posdinemab post-COVID post-hoc analysis post-marketing requirement post-marketing studies postprandial povetacicept pozdeutinurad practice expense practice-changing pre-IPO pre-IPO ' precision neurology preclinical CRO preclinical drug preclinical program preclinical research preclinical studies pregnancy detection pregnancy screening preliminary injunction presbyopia prescribers prescribing habits prescribing rules prescription drug ads prescription renewals prespecified pretomanid prevention antibody preventive healthcare preventive services panel price controls price decline price hike price transparency pricing flaw pricing policies pricing pressures pricing reform prifemilast prioritization priority brands priority vouchers private block trade proactive care product hopping product strategy profit margin profitability programmable RNA medicines programmable biology progressiva project cancellation propane propiolactone protections protein compounds protein drug discovery protein elimination therapeutics protein folding protein levels protein science protein structures protein-based vaccine protein-ligand datasets protein-ligand prediction provider operations pseudobulbar psychedelic medicine psychedelic supply psychiatric trials psychiatry pipeline public biotech public companies public company public health agencies public health crisis public health debate public health guidance public health leaders public servants pulmonary disease spinoff pulsed field ablation pure-play strategy quality assurance quality control violations quantum phenomena questions radiation-free imaging radical transparency radiographic remission radioisotope facility radioisotope supply chain radiological imaging radiotheranostics radiotherapeutic radiprodil ransomware rare blood disorder rare disease reSET (device) real-estate real-time real-time clinical trials real-time disclosure real-time publishing realistic medical scenarios rebate rate rebate schemes rebranding reciprocal tariffs recognition recombinational repair record sales recurrence-free survival recurrent astrocytoma redesable eye drop reduction in force reform refractory large B-cell lymphoma refractory myeloma refusal-to-file regenerative cell therapy registrational study regulatory AI frameworks regulatory RNA regulatory advocacy regulatory alignment regulatory barriers regulatory certainty regulatory change regulatory changes regulatory complexity regulatory consulting regulatory decision regulatory disclosure regulatory dynamics regulatory governance regulatory harmonization regulatory hurdle regulatory innovation regulatory law regulatory meetings regulatory reform regulatory reforms regulatory risk regulatory sandbox regulatory standards regulatory streamlining regulatory submissions regulatory transparency reinstatement relapsed/refractory B-cell non-Hodgkin lymphoma relapsed/refractory large-B-cell lymphoma relapsed/refractory multiple myeloma relatlimab remission rate remote scanning remternetug remyelination renal response renewal representatives reproductive health biotech repurchase reputation rescheduling rese-cel research discontinuation research instrument development research partnerships research program research retraction research study research universities resignations resource shortage respiratory vaccines respiratory virus season restraining order restricted population restructuring charges resume analysis revakinagene taroretcel-lwey revamp revenue dip revenue goal revenue guidance cut revenue target revumenib revyve rezafungin ribonucleoside-diphosphate reductase activity rilvegostomig risankizumab risedronate risk factors risk-based risk-based oversight risperidone risvodetinib rituximab rivalry rivals square robotic HIFU robotic automation robotic knee replacement roll-ups romantasy ' rondecabtagene autoleucel roundtable royalty acquisition royalty management royalty monetization rubrics runway rural healthcare sBLA sac-TMT sacituzumab govitecan-hziy safety signal salanersen sale rule sales guidance sales outlook salicylhydroxamic acid sample stabilization satralizumab scFv scPharmaceuticals scSurvival scale-up scaling not solving scandal scenario school meals science-led storytelling scientific advisors scientific discovery scientist protest screening program scrutiny search behavior seasonal flu secondary blood cancers secondary markets sector rotation secured secured debt securities securities fraud seed financing seed investments seizure drug seladelpar self-administered drug self-administration self-collection devices self-injectable self-injection business self-injection systems self-paying self-serve self-service selpercatinib semiconductor supply chains semiconductor tariffs sensor (device) sequence-based AI serono setrusumab sevasemten seventh shadow AI shakeup sham surgery sham-controlled trial shareholder value shelf registration statement shortage shrinking shrinking budgets shutdowns shuttles sialidase fusion protein sigma-2 receptor single dose single-cell RNA sequencing single-dose vials sirolimus site closure site transfer skin clearance sleep biotech slow awareness small molecule agonists small molecule candidates small molecule design small molecule drug discovery small molecule drugs small molecule inhibitors small molecule medicines small molecule therapies social disadvantage software-as-a-medical-device solid cancers solid tumor cancer solid-state batteries somatic genomics somato-cognitive action network somatropin sonefpeglutide sonrotoclax soquelitinib sorfequiline sortilin sotatercept-csrk sotorasib spatial profiling spatial proteomics specialty diseases specialty drugs spectral imaging speed spesolimab spin-out spinoff spleen exam splice correction splicing correction spotty complaint reporting staff exclusion staff reduction staff reorganization stage IV reduction stake sale stalking horse stance standards characteristics statistical methods stealth stem cell-derived islet cells stem cell-secreted proteins sterile cartridge facility sterile manufacturing steroid-sparing stock plunge stock price stock purchase stock repurchase programs stock sale stock sales stock slide stock slip stockholder stockpile stockpiling strain Big Pharma market pressures strain selection strategic advisory strategic alignment strategic assets strategic collaborations strategic decision-making strategic investors strategic options strategic overhaul strategic pivot strategic plan strategic reserves strategic transformation strategy streamlined process streamlined review streamlined system stroke trial structural changes stuttering pipeline subcutaneous administration subcutaneous elegrobart subcutaneously delivered antibodies sublingual tablets submission delays submission program suboptimal response success rates succession planning suicide suicide warnings sunitinib sunvozertinib superbugs supercomputer superiority trials supplemental approval supply chain exposure supply chain management supply chain resilience supply chains supply shortages supply suspension suppurativa surgical guidance surgical planning surgical robotics surrogacy surrogate endpoint surveillance aspects survival data survival rate survodutide sutacimig suvorexant sweat sensors synovial fibroblasts synthetic construct synthetic royalty syphilis treatment tarcocimab tedromer target-effector pairs targeted alpha therapy tariff avoidance tariff exemptions tariff increase tariff pause tariff threat tarlatamab-dlle tau therapy tau-targeting tau-targeting antibody tavatecan team shutdown team transformation tech partnerships technology innovation technology summits teen suicide telehealth platform tenofovir tenofovir disoproxil fumarate tenure terabytes terminated - RoleStatus therapeutic antibodies therapeutic development therapeutic diversification therapeutic payloads therapist thermal imaging theta/beta ratio third quarter third-party facility three-year thrombotic disease thymic stromal lymphopoietin thymus regeneration thymus-targeted thymus-targeted therapy ticker ties time acceleration tissue models tobevibart top-selling drugs topical amitriptyline topical treatment total health toxic bacteria toxicity profile trade agreement trade compliance trade deficit trade deficits trade policy trade secrets trading training data trans-splicing ribozyme transatlantic trade transdermal cannabidiol gel translational translational biology transposons trauma qualifier traveler treatment approval treatment discontinuations treatment prediction treatment resistance treatment scaling treatment-resistant hypertension trebled trial failure trial results trial site irregularities triple hormone receptor agonist triple seronegative triple therapy triple-G drug triplet combo liver cancer triplet therapy tumor agnostic tumor control tumor response tumor shrinkage tumor-specific antigens tumor-targeting engagers turbulence turnaround strategy twice-yearly type I uACR uUTIs ultra-long acting ultra-rare disease ultra-rare diseases ultra-short regimen unanimous vote unapproved underregulated unicorn startup union strike universal recommendation university lawsuit unmet unreliable unreported deaths upfront cash upfront discounts upgrade upheaval upper-to-lower body segment ratio upstream data urgent care visits urothelial cancer ursodiol utilization qualifier uveitic macular edema vIGA-AD vaccine advisors vaccine advisory panel vaccine agenda vaccine alternatives vaccine approval vaccine delivery vaccine developers vaccine framework vaccine guidelines vaccine industry vaccine injuries vaccine licensing vaccine misinformation vaccine oversight vaccine pipeline vaccine policy vaccine programs vaccine regulation vaccine skepticism vaccine standards vaccine trial valbenazine valley of death value maximization value-based contracts value-based pricing valve disease varegacestat vascular deposit binding vascular intelligence vascular intervention vascular leakage vaso-occlusive crises vector vectorized veligrotug vendor-agnostic verekitug vial stopper defects vidofludimus vilobelimab violation viral shedding viral suppression virtual diagnosis vision improvement visual computing vitamin B12 vobra volixibat von Willebrand Disease vopimetostat vorolanib vote voting voxelotor wage waveLINE-003 wear time wearable biosensor wearable regulations wearable sensors wearable technology healthcare wearables market web navigation webinar calendar webinars weight loss business weight loss data weight loss maintenance weight loss market weight loss medication weight loss obesity weight loss therapy weight maintenance weight regain welireg keytruda kidney cancer wellness apps * * white glove delivery whole-virus wild-type wind-down operations wireless withdrawal of approval workflow automation workforce workforce termination workplace toxicity world 's z-rostudirsen zelenectide zelicapavir zenocutuzumab zetomipzomib ziclumeran zocilurtatug pelitecan zoldonrasib zoliflodacin zongertinib zopapogene imadenovec-drba zorpocabtagene-autoleucel ( zovegalisib Élancé

Show more Show less

Powered by Blogger

X-Data LLC